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The current commercialized Gd(III)-based magnetic resonance (MR) contrast 
agents are small molecules characterized with short blood half-life and nonspecific tissue 
distribution. The accuracy of MR diagnosis involving clinical contrast agents is often 
hindered because of a short diagnostic window and low selectivity of target tissues. 
Macromolecular Gd(III)-based contrast agents are more effective than small molecular 
agents for blood pool imaging with high relaxivity and limited vascular extravasation. 
However, the clinical translation of macromolecular contrast agents is impeded by the 
potential safety concerns associated with their slow excretion and prolonged tissue 
retention. Polydisulfide Gd(III) complexes have been developed as biodegradable 
macromolecular MR contrast agents to facilitate the excretion of Gd(III) chelates and 
alleviate the safety concerns. The agents can be readily degraded and excreted via renal 
filtration with minimal tissue retention. However, the reported polydisulfide Gd(III) 
complexes are based on linear Gd(III) chelates of a DTPA derivative, which has poor 
kinetic stability. In this research, two alternative polydisulfides have been developed to 
minimize the stability issue of the linear Gd(III) ligand. Firstly, polydisulfide Mn(II) 
complexes were developed as gadolinium-free biodegradable macromolecular MRI 
contrast agents. Two polydisulfide Mn(II) complexes based on Mn-DTPA and Mn-
EDTA were synthesized and characterized. Both agents showed comparable relaxivity to 
the reported polydisulfide Gd(III) complexes. The degradations of both polydisulfide
	   iv	  
Mn(II) complexes were demonstrated through in vitro incubation with endogenous free 
thiols. In vitro transmetallation study revealed higher kinetic inertness of the Mn-DTPA-
based agent. In vivo MR evaluation showed preferential contrast enhancement of Mn(II) 
agents in the liver and myocardium. Secondly, polydisulfides based on the more stable 
macrocyclic Gd(III) chelates were developed and evaluated. Two polydisulfide Gd-
DOTA conjugates with charge differences were synthesized and characterized. Both 
agents showed improved relaxivity, and efficient degradability. Both in vitro and in vivo 
transmetallation study revealed higher kinetic inertness of the macrocyclic polydisulfide 
agents than the previously reported linear agents. The effect of charge on 
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The development of contrast agents for magnetic resonance imaging (MRI) has 
been rapidly growing with the expanding clinical needs of MRI, which plays a critical 
role in routine medical diagnosis. As a noninvasive diagnostic modality, MRI is versatile 
in providing extensive information of tissues, including their anatomical structure and 
functional conditions (1-3). Compared to other imaging modalities, MRI has an 
advantage in providing high-resolution image qualities without the exposure of patients 
under ionization radiation. Contrast agents have been applied to further extend the 
clinical potential of MRI. To date, over one third of clinical MR diagnoses are carried out 
with the administration of contrast media, among which gadolinium (Gd)-based agents 
have remained the dominant choice in clinical practices (4-6). These Gd(III)-based 
commercialized agents were small molecular Gd(III) chelates with low tissue selectivity, 
short blood retention, and fast renal elimination (5, 6). Such unfavorable features have 
hindered the application of clinical agents in the more advanced diagnostic challenges, 
such as early detection of cancer.    
The concept of Gd(III)-based macromolecular contrast agent stems from the early 
1990s in an effort to push the clinical potential of MR imaging, especially in the area of 
blood pool imaging, including MR angiography and cancer prognosis (7-10). The
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increase of molecular size has led to dramatically different physiological behaviors of the 
macromolecular agents from the small molecular agents. These agents have limited 
extravasation from the vasculature and longer blood retentions, thus providing blood pool 
specific images with a longer diagnostic window (7). In addition, the macromolecular 
contrast agents generally exhibit higher relaxivity than that of the small molecular agents 
due to reduced molecular rotational tumbling (5). Given these favorable features, 
research interests on macromolecular contrast agents have been expanding over the past 
decade, but their further clinical translation is hindered mainly due to safety 
considerations associated with inefficient elimination (11).   
This chapter will briefly cover reviews on the principle of MRI and contrast 
agents, as well as the advantage and limitation of clinical and experimental 
macromolecular Gd(III)-based contrast agents in terms of efficacy and safety. In the end, 
the rationale for our previous and current research on clinically oriented biodegradable 
macromolecular contrast agents will be summarized.  
 
Magnetic Resonance Imaging  
 Until the early 1970s, the phenomenon of nuclear magnetic resonance was only 
used as an analysis tool to detect local molecular environment and identify compounds in 
chemistry (2). Today, the same principle is utilized as a noninvasive technique to detect 
the internal structure of living subjects. MRI takes advantage of the vast information in 
nuclei signals and uses it as a clinical diagnostic tool for disease detection. In comparison 
to other imaging techniques such as computed tomography (CT) and positron emission 
tomography (PET), MR imaging can provide deep tissue penetration without the 
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requirements of radioactive tracer or radiation exposure. In addition, MRI provides high 
spatial and contrast resolution and is currently the primary imaging tool for soft tissue 
anatomy (1). 
 
Working Principles of MRI 
Spin of Nuclei and Precession in Magnetic Field 
MRI generates images from the signals produced by the nuclei of hydrogen atoms 
in common molecules of the human body such as water and fat. These hydrogen atoms 
have unpaired protons that add spin to the nuclei. Spin is the intrinsic property of protons 
and has its individual axis around which the protons rotate. Since proton is positively 
charged, the spin creates a magnetic moment to the proton, which acts like a small 
magnet. When exposed to a large external magnetic field (B0) generated by the MRI 
machine, the magnetic moments of protons are affected by B0. In order to achieve 
minimum energy state, a torque will act on each nucleus and align them parallel or 
antiparallel with the external magnetic field. As the axis of each nuclei spin aligns with 
the external magnetic field, their magnetic moments undergo a process called precession. 
The frequency of this nuclei precession is called the Larmor frequency, ωL, which is 
proportional to the strength of the magnetic field, B0 : 
ωL= γB0                (1) 
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Radio Frequency Excitation and Signal Collection 
 The sum of the net magnetic moments of all the nuclei in a given tissue can be 
represented by the vector sum of their magnetic moments as nuclear magnetization, 
denoted M, which can be divided into transverse and longitudinal components. The Radio 
Frequency (RF) receiver coil detects the rotation of the traverse component of M. As the 
magnetic flux of the transverse component oscillates in the receiver coil, an electrical 
signal is generated as the MR signal. Upon equilibrium, the nuclei precess at random 
phases, causing the transverse components of M to cancel out and leaving the 
longitudinal components as the net equilibrium magnetization, M0. M0 occurs as a slight 
excess of nuclei preferentially align parallel instead of antiparallel with the external field 




−γhB0 / k BT                     (2) 
where N ↑ N ↓  is the ratio of numbers of nuclei parallel versus antiparallel with the 
external field, h is Plank’s constant, kB is Boltzmann’s constant, and T is the absolute 
temperature of the sample. The equation illustrates that the equilibrium magnetization M0 
is related to the strength of the external magnetic field. In order to manipulate this net 
magnetization, an excitation pulse at the Larmor frequency is applied, inducing the net 
magnetization to tip away from the longitudinal direction to the tranverse direction, as 
shown in Figure 1.1. The excitation pulse in the form of a magnetic field, B1(t), causes 
the transverse magnetization to rotate. The rotation continues after B1(t) is switched off, 
producing an alternative voltage that can be detected by the RF receiver coil, which will 
eventually disappear when the net magnetization decays back to M0.  




T1 and T2 Relaxation  
 Due to intramolecular and intermolecular forces, the excited nuclei will 
eventually relax back to its equilibrium state, which is termed longitudinal relaxation. As 
the timescale for longitudinal relaxation to occur is designated T1, the longitudinal 
relaxation is also called T1 relaxation. T1 relaxation is caused by interactions between the 
nuclei and their environment, and thus varies with different molecules and tissue types to 
which the nuclei are subjected. Therefore, T1 is determined by the tumble of a molecule 
Figure 1.1. Schematic of the change in net magnetization vector, M0, during MR scans
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in its surrounding environement. The T1 value is shortest as the tumbling rate is closest to 
the Larmor frequency. In order to obtain signal contrast, excitation and signal collection 
is performed repeatedly during an MR scanning, and the degree of longitudinal 
magnetization recovery between each excitation is different. Therefore, the repetition 
time (TR) of successive excitation becomes important to determine different tissue types, 
as tissue with long T1 value cannot regain full magnetization during short TR excitation. 
In general, MR images acquired during short TR are called ‘T1-weighted’ images. 
 The amplitude of the transverse component of the magnetization depends on the 
phase coherence of the nuclei. Similar to longitudinal relaxation, the transverse 
component will decay as well after the initial excitation. However, the transverse 
relaxation occurs at a faster rate than the longitudinal relaxation. There are generally two 
sources of dephasing that lead to transverse relaxation. One of them comes from the 
interaction of the local magnetic fields between the neighboring molecules. The time that 
it takes is known as T2.  Molecules in constant motion counteract the effect of local 
magnetic fields and therefore have a slower T2 relaxation. Macromolecules hence exhibit 
very short T2 value since they cannot move freely in their environment. The other source 
of dephasing comes from the inhomogeneity of the external magnetic field applied. The 
time value of this process is denoted T2*. The ability to be magnetized by the external 
fields varies among molecules. Depending on their electron configuration, ferromagnetic 
materials such as most metals are more susceptible to magnetization than diamagnetic 
and paramagnetic materials. Both T2 and T2* relaxation can be utilized to gain image 
contrast.   
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MR Contrast Agents 
In order to improve image contrast between normal and diseased tissues, there has 
been a surge in the development of induced-image contrast using exogenous contrast 
agents. In the late 1970s, paramagnetic agents were first discovered to enhance tissue 
discrimination by altering the relaxation time of water protons (4). From a physical point 
of view, the MR contrast agents can be classified into T1 and T2 agents according to the 
relaxation time they predominantly influence. Contrast agents that mainly affect the T1 
relaxation rate of protons is termed T1 agents. During the scanning of T1-weighted images 
using MR sequences with comparatively short repetition time (TR), the T1 agents 
increase the signal intensities of the target tissues and generate positive contrast. The T2 
contrast agents mainly affect the T2 relaxation of protons. They are used in T2-weighted 
imaging scanning with MR sequences of relatively long echo time (TE). The T2-weight 
imaging scans will result in decreased signal intensities in the target tissues, leading to 
darkening of target contrast.     
Paramagnetic or superparamagnetic metal species, such as manganese (Mn), iron 
(Fe), and the lanthanides, possess high magnetic moments that can significantly enhance 
the relaxation of excited nuclei. They have been considered promising candidates for MR 
contrast agents. So far, only three metal species, Mn(II), gadolinium (Gd), and Fe(III), 
have successfully entered clinical application, among which Mn(II) and Gd(III) are T1 
agents and Fe(III) is T2 agent (5, 12, 13). Gd(III)-based contrast agents are most widely 
used in clinical applications among all current clinical available MR contrast agents. 
Over the past decades, Gd(III) continues to be the dominant choice in the development of 
MR contrast agents due to its superior relaxation enhancing property granted by the large 
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number of unpaired electrons on its outermost shell and its symmetrical molecular 
structure (4, 5). Free Gd3+ ions have been characterized with high relaxivity, but are too 
toxic to be given directly (14, 15). Highly stable Gd(III) chelates have been developed to 
minimize the acute toxicity of Gd3+ (5).  
 
Design Rationale for MR Contrast Agents 
In general, contrast agents are designed to achieve three major goals regarding 
effectiveness and safety. Firstly, the agent should generate adequate relaxivity 
enhancement to increase the sensitivity of MR imaging at acceptable dose. In particular, 
the agents should be able to increase the relaxation rate of target tissues in order to cause 
enough contrast for detection. Secondly, the contrast agents should possess certain tissue 
specificity in order to discriminate the tissue of interest from normal tissues. Thirdly, the 
contrast agents need to be biocompatible and safe to apply. In the case of Gd(III)-based 
contrast agents, their ligand structure need to have higher affinity to the Gd3+ ions over 
the endogenous metal ions to minimize their possible interference in vivo for safety 
purposes. In addition, the Gd(III) complexes also need to be readily excreted after the 
MR examination to ensure minimal tissue retention of the agents. The efficacy 
requirement can conflict with the safety need when designing a contrast agent. For 
instance, agents with rapid clearance might have short blood retention for effective MR 
evaluation, whereas agents with high relaxivity might exhibit longer tissue accumulation. 
Therefore, successful design of clinical applicable contrast agents should balance the 
considerations between efficacy and safety.    
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Small Molecular Commercial Gd(III)-based Contrast Agents 
Chemical Structure  
The current clinically available Gd(III)-based MR contrast agents are small 
molecular Gd(III) complexes, formed between Gd(III) and different polyamino-
polycarboxylic ligands (4-6). Based on ligand structure, the current commercial Gd(III)-
based contrast agents can be categorized into two distinct categories: 1) the  ‘linear’ 
chelates based on acyclic triamine (diethylenetriamine) derivatives, including Gd-DTPA 
(Magnevist®), Gd-DTPA-BMA (Omniscan®), Gd-DTPA-BMEA (OptiMARK®), Gd-
BOPTA (MultiHance®), Gd-EOB-DTPA (Primovist®), and MS-325 (Vasovist®); 2) the 
‘macrocyclic’ chelates based on the twelve-membered tetraazamacrocyclic cyclen 
(1,4,7,10-tetraazacyclododecane) derivatives, including Gd-DOTA (Dotarem®), Gd-HP-
DOTA (ProHance®), and Gd-BT-DOTA (Gadovist®) (5). In both types of chelates, Gd3+, 
with nine coordination sites, is trapped in the cavity of the polyamino-polycarboxylic 
ligands with eight coordination bonds, leaving one coordination site for inner sphere 
water binding (4, 5). Depending on the charge of their corresponding ligands, the overall 
Gd(III) complexes are either electronically neutral (nonionic) or charged (ionic). Thus, 
the current clinical Gd(III)-based agents can be further devided into four catogeries: the 
ionic linear, the nonionic linear, the ionic macrocyclic, and the nonionic macrocyclic 
chelates (Figure 1.2).  
All linear Gd(III) agents are formed between Gd3+- and DTPA-derived ligands with 
open-chain structure. As shown in Figure 1.2, the ionic linear chelates, including Gd-
DTPA, Gd-BOPTA, Gd-EOB-DTPA, and MS-325, contain three amino nitrogen atoms 
and five negatively charged monodentate carboxylic oxygen atoms that bind with Gd3+,  





	  	  	  
Figure 1.2. Structure of clinical Gd(III)-based contrast agents 
                                                                                                                                             	  
	  
11 
resulting in two overall negative charges of the Gd(III) complexes. The negative charges 
of the overall chelates may result in lower dose tolerance due to increased osmolality and 
viscosity of the injection solution (5, 16-18). As a result, the ionic Gd(III) chelates are 
generally formulated with positively charged cations, such as the amino sugar meglumine 
(with Gd-DTPA and Gd-BOPTA) and Na+ (with Gd-EOB-DTPA and MS-325), to form 
neutralized solution with lower osmolality and viscosity (16). The nonionic linear Gd(III) 
chelates, including Gd-DTPA-BMEA and Gd-DTPA-BMA, were originally developed to 
lower the osmolality of the injection solution as well. The structure of the nonionic linear 
Gd(III) is similar to their ionic analogue, except that two of the ionic bonds between Gd3+ 
and the negatively charged carboxylic oxygen in the ionic chelates are substituted by the 
weaker nonionic bonds between Gd3+ and the neutral carbonyl oxygen atoms in the 
nonionic chelates (Figure. 1.2). 	  
The macrocyclic Gd(III) chelates are formed between Gd3+ and DOTA derivatives 
with 12-membered macrocycilc polyaminocarboxylates ring. The ionic macrocyclic 
Gd(III) chelate, Gd-DOTA, has four amino nitrogen atoms and four monodentate 
carboxylic oxygen atoms that bind to Gd3+, leading to a negative overall charge of the 
complex. In comparison, one of the negatively charged carboxylic oxygens in the ionic 
Gd-DOTA is replaced by less powerful electron donor oxygen atoms such as the 
alcoholic oxygen for nonionic macrocyclic Gd(III) chelates, including Gd-HP-DO3A and 
Gd-BT-DO3A. For Gd-HP-DO3A, a hydroxypropyl group is used to substitute one 
carboxylate group of Gd-DOTA, whereas a bulky 2,3-dihydroxy-(1-hydroxymethyl)-
propyl group was used for the replacement in Gd-BT-DO3A (Figure 1.2).  	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Chelate Stability-Safety of Gd(III)-based Contrast Agents 
Free Gd3+ is highly toxic. It is structurally similar to Ca2+, and can act as a potent 
inhibitor for many types of voltage-gated calcium channels and calcium dependent 
enzyme activities at very low concentrations (in the range of nano- to micromolar 
concentrations) (14, 15). Consequently, a small amount of free Gd3+ ions can cause 
inhibition of calcium-involved physiological functions such as smooth, skeletal, cardiac 
muscle contraction, nervous influx transmission, blood coagulation, liver function, etc. 
(14, 15). In addition, free Gd3+ is known to depress the reticuloendothelial system (15), 
inhibit phagocytosis of Kupffer cells (19, 20), and increase the expression of certain 
hepatic cytokines (21). The acute toxicity of free Gd3+ can be substantially alleviated 
through chelation of Gd(III) using appropriate coordinating ligands (5). For instance, the 
intravenous LD50 of Gd-DOTA in mice (10.6 mmol/kg) was 30-fold higher than that of 
GdCl3 (0.35 mmol/kg) under similar conditions, indicating significant increase of drug 
safety after complexation (22). Chelate stability is therefore a crucial factor influencing 
the safety profile of Gd(III)-based contrast agents. 
Chelate stability is generally described using two concepts: thermodynamic 
stability and kinetic inertness (or kinetic stability). For Gd(III) chelates, thermodynamic 
stability emphasizes the extent of complex formation under certain conditions at 
equilibrium. It is often quantified using stability constants, indicating the bonding energy 
between Gd(III) and its corresponding ligands. Thermodynamic stability is independent 
of how equilibrium is reached and hence gives no information of the reaction process. 
Kinetic inertness, on the other hand,  focuses on the course of complex formtion and 
therefore mainly deals with reaction rates and mechanisms (23, 24). 




The thermodynamic stability of Gd(III) chelates reflects the affinity of Gd3+ and 
its ligand. When Gd(III) is complexed, a thermodynamic equilibrium occurrs between the 
metal [Gd], its ligand [L] and the chelate [GdL]: 
                                         [Gd] + [L] D [GdL]                                                   (1) 
From the equilibrium equation, the thermodynamic stability constant is defined as:  
                                            Ktherm =[GdL] ⁄ ([Gd]*[L])                                                 (2) 
 In general, the stability of Gd chelate is expressed in the form of log Ktherm. The higher 
the value of log Ktherm, the more stable is the chelate, and the lower chance of free Gd3+ 
and free ligands release at equilibrium, both of which are poorly tolerated in vivo.   
Since Ktherm applies only at at highly basic conditions where the ligand is not 
protonated, a more appropriate description, the conditional thermodynamic constant log 
Kcond that takes into account the protonation forms of the free ligand at physiological pH 
(pH=7.4), was introduced. At equilibrium, Kcond is defined as (25): 
         Kcond = [GdL] ⁄ [Gd]{[L] + [HL] + [H2L] + …+ [HnL]}                       (3) 
where [HL], [H2L], and [HnL] are the different protonation species of the free ligands. 
From equation (2) and (3), the relationship between the theoretical (Ktherm) and 
conditional thermodynamic constants (Kcond) are derived as:  
                                  Kcond = Ktherm [L] ⁄ LT                                                               (4) 
where LT is the total concentration of the uncomplexed ligands at physiological pH，{[L] 
+ [HL] + [H2L] +…+ [HnL]}. Since all Gd(III) ligands have significant extent of 
protonation at pH 7.4, the conditional thermodynamic constant log Kcond is always 
substantially lower than the theoretical thermodynamic constants log Ktherm, as shown in 




Although the current clinical Gd(III) agents are classically considered highly stable 
with large thermodynamic constants, their log Ktherm and log Kcond can be dramatically 
different due to structural impact. For Gd(III) complexes, ionic bonding is the 
predominant chemical force that keeps the chelates intact . Therefore, stability of Gd(III) 
chelates essentially reflects the extent of electrostatic interactions between the Gd3+ and 
the donor groups of the ligand (e.g., Polyaza-carboxylate). Such interactions are mainly 
influenced by two structural factors, molecular configuration (complex conformation), 
and chelate ionicity (ligand basicity).  
As demonstrated in Table 1.1, the thermodynamic stability constants of the 
macrocyclic Gd(III) chelates are similar or 2-3 magnitude higher than those of the linear 
chelates, indicating the macrocyclic effect on chelate stability (28, 29). In comparison to 
the linear ligands, the macrocyclic ligands provide a more rigid and compact cavity for 
 
 Table 1.1 Structure and thermodynamic constants of clinical Gd(III)-based contrast 
agents (5, 6, 17, 26, 27). 
 







MultiHance® Gd-BOPTA 22.6 18.4 
Primovist® Gd-EOB-DTPA 23.5 18.7 
Vasovist® MS-325 22.1 18.9 
Omniscan® Gd-DTPA-BMA Nonionic 
 
16.9 14.9 
OptiMARK® Gd-DTPA-BMEA 16.6 15.0 
Dotarem® Gd-DOTA 
Macrocyclic 
Ionic 25.6 19.3 
ProHance® Gd-HP-DOTA Nonionic 
 
23.8 17.1 
Gadovist® Gd-BT-DOTA 21.8 14.7 
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the entrappment of Gd3+ (30). This pre-organized conformation is found well suited for 
Gd3+, incorporating the transitional metal ions tightly with coordination bonds provided 
by the oxygen and nitrogen donors. NMR experiments have demonstrated this high 
rigidity of the DOTA structure, which requires relatively high activation energy to break 
the barrier for both complexation and de-complexation reactions (31). Therefore, the 
conformation of the macrocyclic ligand assures high thermodynamic stability of its 
corresponding ligands (32, 33). Structures of the pendant arms that have certain impacts 
on the rigidity of the ligand can consequently affect the thermodynamic stability of 
macrocyclic chelates (34). In comparison, the linear ligands exhibit higher flexibility and 
are more susceptible to conformational change and loss of Gd3+ in solution. Overall, the 
conformational differences between the two structures have a major influence on their 
thermodynamic stabilities.  
The influence of chelate ionicity, or ligand basicity, can also be derived from 
Table 1.1. Ligand basicity is a quantitative depiction of the electronegative intensities on 
the polyaza-carboxylate scaffolds, which directly affect the charge-charge interactions 
between the ligands and the Gd3+ ions and thus the thermodynamic stability of the 
resulting chelates (29, 35). The overall basicity of a ligand (pKb) is caculated as the 
summary of the protonation constants of each donor atom of the ligand (29). The value of 
Ktherm varies through modifications of the pendant arms of DTPA and DOTA, which are 
carried out to enable different functionalities and pharmacokinetic patterns of the 
corresponding Gd(III) chelates. Ligand modifications include substitution of the 
carboxylic acids on the pendant arms of DTPA or DOTA with amides, alcohols, and 
phenols for clinical agents. These modifications often decrease the basicity of the ligands 
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and result in weaker chelates. As a result, the original forms of both linear and 
macrocyclic chelates (Gd-DTPA, Omniscan®, and Gd-DOTA, Doteram®) are 
characterized with higher thermodynamic stability than their respective derivatives. For 
linear chelates, the diamide derivatives, Gd-DTPA-BMA (Omniscan®), and Gd-DTPA-
BMEA (OptiMARK®), compromise two negatively charged donor atoms of the original 
ligand and lead to significant decrease of log Ktherm from 22 to 15~19 as shown in Table 
1.1. In contrast, the thermodynamic stability of macocyclic chelate is only slightly 
affected after replacement of one acetate group with an alcohol-containing group (e.g., 
Gd-HP-DOTA, ProHance®, and Gd-BT-DOTA Gadovist) (29, 36).   
In addition to clinical agents, the effect of basicity on thermodynamic stability 
was also observed for a variety of experimental ligand derivatives. For the macrocyclic 
chelates, modification of the pendant arms can affect the basicity of the nitrogen atoms 
on the macrocyclic ring and lead to change of thermodynamic stability of the chelates. 
For instance, the replacement of four acetate pendant arms of DOTA with 
methylphosphonic acid improves log Ktherm due to increased basicity of the four donor 
nitrogen atoms (37, 38), yet introduction of four monoesters of methylphosphonic acid 
for the replacement resulted in weaker macrocyclic chelates due to decreased nitrogen 
basicity (39-42). However, this impact on nitrogen basicity was found minor when the 
substitution happened on single pendant arms of the macrocyclic chelates (43, 44). This 
also explains the relatively minor change of thermodynamic stability of Gd-HP-DOTA 
and Gd-BT-DOTA from Gd-DOTA as mentioned above. Similar effects also apply to  
the DTPA chelates, of which double or multiple modifications of the pendant arm result 
in greater change of thermodynamic stability than that resulted from single modification. 
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In summary, the thermodynamic stability of Gd(III) chelates is affected by the ligand 
basicity, which is determined by the number and structure of the modified pendant arms 
of DTPA or DOTA. 
The thermodynamic stability constants of Gd(III) chelates ( log Ktherm and log Kcond) 
are important parameters in terms of formulation, since formulation solutions have 
adequate time to equilibrate during their relatively long shelf-life (generally 2-3 years for 
the marketed Gd(III)-based contrast agents). From the thermodynamic point of view, 
Gd(III) agents with relatively low conditional stability are generally formulated with an 
excess of free ligands or different salts to reduce the chance of Gd3+ dissociation in the 
pharmaceutical solutions over their shelf lives (5, 6).  
Although the thermodynamic stability constants, log Ktherm and log Kcond, appear 
accurate in predicting the stability of Gd(III) complexes under simple in vitro conditions, 
they are insufficient to depict the actual inertness of Gd(III) agents when exposed to the 
much more complicated in vivo environment. After intravenous injection, the clinical 
agents are exposed to the blood and other body fluids that are composed of relatively 
complex and intricate milieus with enormous amount of endogenous ligands and metal 
species (17) . The presence of these ingredients can greatly threaten the stability of Gd(III) 
agents via competitive reactions. Endogenous metal cations such as Fe3+, Zn2+, Ca2+, and 
Cu2+ can replace Gd(III) from its chelate, causing the release of Gd3+ ion which can then 
be complexed with metal-binding proteins and small endogenous ligands such as citrate, 
glutaminate, CO32-, OH-, PO43-, etc. This phenomenon of in vivo metal-metal exchange 
reaction is termed “transmetallation” and regarded as the main mechanism of in vivo de-
chelation for Gd(III) complexes (17, 24).   
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In order to study the in vivo fate of Gd(III) complexes from the thermodynamic 
aspect, thermodynamic selective constant (Ksel) is introduced to describe the chance of 
transmetallation according to the following equation (25, 45-47): 
   GdL + [M]2+ D Gd3+ + [ML]-                                                  (5) 
where M is the bivalent metal cation that substitutes Gd3+ from the original chelate. 
Different definitions of Ksel have been reported in the literature (5, 25, 33, 35). A 
simplified interpretation takes into account the differences in thermodynamic stability 
constants between the Gd(III) chelates (GdL) and the corresponding metal complexes 
(ML), and defines the thermodynamic selective constant Ksel at equilibrium using the 
following equation: 
log Ksel =log KGdL - log KML                                                      (6) 
The thermodynamic stability constants of chelates between endogenous metal and 
various Gd(III) ligands are listed in Table 1.2. In addition, more complicated definitions 
have been developed, trying to cover all possible competition reactions such as the 
binding of released Gd3+ with endogenous ligands (48).  
 










DTPA 22.1 18.3 10.7 21.4 
DTPA-BMA 16.9 12.0 7.2 13.0 
DOTA 25.8 21.0 17.2 22.6 
HP-DOTA 21 19.4 14.8 22.8 
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Differences in vitro and in vivo approaches have been reported using the 
thermodynamic selective constant (Ksel) to predict the in vivo toxicity of Gd(III)-based 
contrast agents. However, none of these methods correlate well with the actual in vivo 
stability of various Gd(III) complexes. The thermodynamic stability approaches are 
limited due to two major reasons. Firstly, the actual in vivo equilibrium between the 
endogenous ingredients and Gd(III) complexes is too complicated to be well simulated 
via current thermodynamic models. More importantly, the prediction of thermodynamic 
approaches can be biased since the methods are based only on the final state of 
thermodynamic equilibrium without consideration of the dissociation processes. For 
chelates with high thermodynamic stability, such as the macrocyclic Gd(III) complexes,  
the actual time to reach equilibrium can be dramatically longer than the excretion time of 
the agents due to their high in vivo kinetic inertness. In such cases, the thermodynamic 
models are of little physiological importance, whereas the kinetics of chelate dissociation 
are critical in understanding the in vivo stability of Gd(III) agents.  
 
Kinetic Inertness  
Compared to thermodynamic stability, kinetic inertness is more relevant to the in 
vivo fate of Gd(III)-based contrast agents by exploring the rate and mechanisms of 
chelate dissociation reaction. As mentioned in the thermodynamic stability section, the 
dissociation of Gd3+ can occur via two major mechanisms: dechelation and 
transmetallation.  
 Dechelation kinetics. Dechelation is the simplest route of dissociation for Gd(III) 
complex, described as:  
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GdL D Gd3+ + L                                                           (7) 
The reaction can happen through two mechanisms: spontaneous or proton-assisted 
dissociation (47). The rate of dissociation (kdiss) and dissociation half-life (T1/2) are often 
used as quantitative parameters to evaluate the dechelation process. Various in vitro 
studies have been carried out to determine the dissociation rate of different Gd(III) 
chelates. In general, the dissociation is slow at physiological pH and increases as pH 
decreases (49). In consequence, the measurement of dissociation rate is normally carried 
out at very acidic conditions (pH ≈1.0 or 3.0) to amplify the phenomenon (50). In such 
acidic mediums, the dissociation of Gd(III) chelates appeared as a pseudo-first-order 
reaction with the dissociation rate defined as: 
Dissociation rate = kdiss [H+][GdL]                                                 (8) 
Since [H+] is considerably larger than [GdL], it can be considered as constant [H+]0, then 
the equation can be simplified as:  
 Dissociation rate = kobs [GdL]                                                     (9) 
where  
kobs = kdiss [H+]0                                                                    (10) 
The dissociation rate kobs is determined as the slope of the curves ln[GdL]t = f(t) (50).   
Although the reported values of kobs and T1/2 for a specific Gd(III) chelate varies 
depending on the experimental conditions and methods (50-54), a general relationship 
between chelate structure and dissociation rate is observed. The dissociation of the linear 
chelates is dramatically faster than that of the macrocyclic chelates, indicating relatively 
high kinetic lability of the linear chelates. Among the linear chelates, the nonionic 
bisamide linear chelates Gd-DTPA-BMA (Omniscan®) and Gd-DTPA-BMEA 
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(OptiMark®) exhibit faster dissociation than the ionic chelates (55, 56). Such influence 
of ionic strength on dissociation rates is observed but not as significant for the 
macrocyclic chelates in comparison to that for the linear chelates (24). The order of 
dissociation rates among the macrocyclic Gd(III) agents is: Gd-HP-DOTA > Gd-BT-
DOTA > Gd-DOTA, indicating higher kinetic inertness of the ionic macrocyclic chelate 
than that of the ionic macrocyclic chelates (24). Between the two nonionic chelates, the 
dissociation rate of Gd-BT-DOTA is slightly lower than that of Gd-HP-DOTA, indicating 
higher kinetic inertness of Gd-BT-DOTA. This is possibly due to the bulky side chain of 
Gd-BT-DOTA that provides higher steric hindrance against the conformational change 
required for dechelation (57).   
Transmetallation kinetics. Transmetallation is generally considered as the major 
route of Gd3+ loss in vivo given the intricate physiological environment Gd(III)-based 
contrast agents are subjected to after application. Transmetallation of Gd(III) chelates 
leads to Gd3+ release through replacement of chelated Gd(III) by endogenous metal 
cations such as Zn2+, Cu2+, Ca2+, and Fe3+.  The exchange reactions can happen via two 
mechanisms: 1) spontaneous or proton-assisted dechelation of Gd3+ followed by rapid 
complexation between the free ligands and endogenous metal ions; 2) direct attack of 
endogenous metal cations on the Gd(III) chelates (49). Although transmetallation of 
Gd(III) chelates is of significant physiological relevance, it is more complicated to depict 
than the dechelation kinetics. Both in vitro and in vivo studies have been conducted to 
understand the structural impact of Gd(III) chelates on transmetallation (17, 24).   
All reported in vitro studies tried to quantify the extent of transmetallation through 
incubation of Gd(III) chelates with solutions containing the endogenous metal cation 
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species (24, 47, 50, 55, 58, 59). Various direct or indirect methods have been applied to 
measure the loss of Gd3+ after in vitro incubation. In one study, different types of Gd(III) 
chelates were incubated with equimolar of Zn2+ or Cu2+ in a phosphate solution for 15 
minutes. If transmetallation happened in this case, the dissociation of Gd3+ would then 
react with the phosphate anions to form precipitated GdPO4. Based on this assumption, 
the amount of precipitated GdPO4 was measured as an indication of transmetallation (50). 
The results demonstrated that the macrocyclic chelates Gd-DOTA and Gd-HP-DOTA 
were kinetically inert against Zn2+ or Cu2+ transmetallation, whereas significant loss of 
Gd3+ were observed for the linear chelates Gd-DTPA and Gd-DTPA-BMA. Similarly, 
some other in vitro transmetallation studies were carried out under different experimental 
conditions, all leading to the same conclusion that macrocyclic chelates were kinetically 
more stable against transmetallation than the linear chelates (24).  
Despite direct measurement of the precipitated GdPO4, another in vitro 
relaxometric approach is developed to indirectly quantify the loss of Gd3+ after 
incubation of Gd(III) chelates with Zn2+ in phosphate solutions at physiological pH (60, 
61). Since the precipitated Gd(III) species (GdPO4) have negligible impact on the 
relaxation rate of water, a decrase of relaxation rate over time R1(t) would be observed if 
transmetallation happened, the magnitude of which is related to the proportion of the 
precipitated GdPO4. According to this rationale, the time-course of R1(t)/R1(t=0) is drawn 
and compared for different clinical Gd(III) chelates. Three distinct classes of Gd(III) 
chelates with different stability against in vitro transmetallation are concluded from the 
graph: the most kinetically stable macrocyclic chelates (Gd-DOTA, Gd-HP-DOTA, and 
Gd-BT-DOTA), the moderate kinetically stable ionic linear chelates (Gd-DTPA, Gd-
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EOB-DTPA, Gd-BOPTA, and MS325), and the least kinetically stable nonionic linear 
chelates (Gd-DTPA-BMA and Gd-DTPA-BMEA).   
Various in vitro incubation studies of Gd(III) chelates have arrived at the same 
conclusions regarding the structural impact on transmetallation. Consistent with the trend 
found on thermodynamic stability, chelate conformation and ionicity are demonstrated as 
the two major structural factor influencing kinetic stabilily of Gd(III) chelates, of which 
the impact of chelate conformation is predominant. In general,  linear chelates are more 
susceptible to transmetallation than macrocyclic chelates due to their flexible backbone 
structure, providing relatively high conformational mobility (62). In order to improve the 
kinetic stability of linear chelates, bulky functional groups, such as in the case of Gd-
EOB-DTPA, Gd-BOPTA, and MS325, are introduced to increase the steric hindrance for 
conformational change (63). As mentioned in the previous section, chelate ionicity 
reflects the bonding between Gd3+ and its corresponding ligands, among which ionic 
bonding is the strongest. As a result, the ionic complexes are generally more stable 
against transmetallation than their nonionic analogues for both macrocyclic and linear 
Gd(III) chelates.  
In vivo, the Gd(III)-based contrast agents are subjected to a much more 
complicated environment in comparison to the conditions of in vitro transmetallation 
studies. Disparate from in vitro, dissociation of Gd3+ in vivo can be a result of synergetic 
effects of multiple factors such as endogenous ions, enzymes, and other biological 
elements. Therefore, the in vitro data are not adequate to predict the kinetic stability of 
Gd(III)-based contrast agents in vivo. Since dissociation of Gd3+ cannot be directly 
measured in vivo, the kinetics of Gd(III) chelates on animals or human after 
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administration of various Gd(III) agents are infered through assessment of long-term 
tissue Gd(III) deposition and analysis of blood samples and urine metabolites (24). 
Tissue retention of Gd(III) has been used to determine the in vivo stability of 
Gd(III) chelates. For most clinical Gd(III) agents, the majority of injected chelates would 
be excreted intact through renal elimination within 24 hours after administration, 
resulting in similar pharmacokinetics and biodistribution patterns (50, 51). The data begin 
to separate a week after administration, showing distinct tissue depositions among 
various Gd(III) chelates, which is interpreted as the result of different Gd3+ release from 
the chelates. Once dissociation happened, Gd3+ would complex with endogenous anions 
such as citrates and phosphates, and then be transported and deposited in different tissues. 
Thus, the amount of Gd(III) retention in tissues is considered to correlate with the extent 
of Gd3+ dissociation among different Gd(III) chelates, indicating their kinetic stability in 
vivo. 
 Various preclinical animal studies have been conducted to trace the residual 
Gd(III) in healthy mice or rats after administration of Gd(III) chelates using Gd isotopes 
such as 153Gd and 154Gd (50, 51, 59, 64). In one study, for instance, the tissue deposit of 
153Gd-labelled formulations of Gd-DTPA, Gd-DTPA-BMA, Gd-DOTA, and Gd-HP-
DO3A on mice and rats were monitored at various time-points post injection for up to 14 
days (65). Significant differences were demonstrated for the whole body, liver, and femur 
Gd(III) residuals 14 days post administration of various Gd(III) chelates. In comparison, 
the macrocyclic chelates Gd-DOTA and Gd-HP-DOTA showed minimal Gd(III) 
retention, the ionic linear chelate Gd-DTPA exhibited slightly higher Gd(III) deposit and 
the nonionic linear chelate Gd-DTPA-BMA resulted in the greatest Gd(III) residual, three 
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times higher than that of Gd-DTPA. However, since the residual Gd(III) species cannot 
be identified using the isotope approach, this study alone was not adequate to verify Gd3+ 
dissociation as the cause of long-term Gd(III) retention. The authors then compared the 
tissue retentions of Gd(III) between formulated and unformulated Gd-DTPA-BMA as an 
indirect approach to demonstrate the relationship between Gd3+ dissociation and Gd(III) 
deposition. The results demonstrated that addition of extra Gd(III) ligands Na[Ca-DTPA-
BMA] in the formulated solution dramatically reduced the whole body Gd(III) retention 
from 1 % to 0.3 % of the injected dose, suggesting association between in vivo Gd3+ and 
long-term Gd(III) deposit in tissues. Other similar studies have been carried out, leading 
to results indicating the same order of in vivo stability among various Gd(III) chelates as: 
macrocyclic chelates > ionic linear chelates > > nonionic linear chelates, which was 
consistent with the conclusions from in vitro kinetic studies (24).  
The human relevance of these animal data was demonstrated in clinical studies 
with patients of normal renal function, the impairment of which may lead to dramatic 
increase of Gd(III) retention as renal filtration was the major excretion route for Gd(III) 
chelates (66, 67). In one study, the authors analyzed Gd(III) residuals in the bones of 
patients receiving hip transplant 4 days after contrast-enhanced MRI, during which either 
Gd-HP-DO3A or Gd-DTPA-BMA was administered at clinical dose (0.1 mmol/kg) (66). 
The Gd(III) bone retention was measured using inductively coupled plasma (ICP) atomic 
emission and ICP mass spectroscopy in the consecutive study (67). The results 
demonstrated significantly higher deposit of Gd(III) in the bones of patients receiving 
Gd-DTPA-BMA than that of patients receiving Gd-HP-DOTA. This difference could 
indicate greater in vivo kinetic lability of Gd-DTPA-BMA over Gd-HP-DOTA. However, 
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it was inadequate to confirm Gd3+ dissociation due to limitation of the analytical methods 
that only provide information on the Gd(III) element rather than the species of Gd(III) 
deposits. Nevertheless, as shown in animal studies, the clinical studies also demonstrated 
higher Gd(III) retention of the linear chelates, especially the nonionic linear chelates than 
that of the macrocyclic chelates, indicating a similar trend of in vivo stability among 
various Gd(III) agents.  
Transmetallation has been regarded as the major route of in vivo Gd3+ 
dissociation from Gd(III) chelates. It was extensively investigated in both animal and 
clinical studies (58, 68-72). Theoretically, transmetallation can happen between Gd(III) 
chelates and any endogenous cations with good affinity to Gd(III) ligands, such as Zn2+, 
Cu2+, Ca2+, and Fe3+. In practice, only the Zn2+-mediated transmetallation of Gd(III) 
chelates has been confirmed by current in vivo transmetallation studies, possibly due to 
the readily accessibility of Zn2+ in blood. Among the various endogenous cations, Zn2+ is 
the most availabe due to its relatively high blood concentration (55-125 µmol/L) and 
good ligand affinity. In comparison, Cu2+ level is low (1-10 µmol/L) in plasma, Ca2+ ions 
have relatively low ligand affinity, and Fe3+ ions are tightly bound to plasma proteins (69, 
73). By far, most in vivo transmetallation have been demonstrated through analysis of 
plasma or urine Zn(II) content before and post administration of Gd(III) chelates. In both 
animal and clinical studies, significant increase of urine Zn(II) level was observed for the 
linear chelates, whereas no detectable Zn(II) was discovered for the macrocyclic chelates 
(17). One clinical study on healthy patients showed almost 3-fold higher of the urine 
Zn(II) content post application of Gd-DTPA-BMA than that of post application of Gd-
DTPA (58), indicating dramatically greater extent of transmetallation for the nonionic 
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linear chelates in comparison to the ionic linear chelates. Similar results were 
demonstrated in other clinical and animal studies (11, 17). In summary, both animal and 
clinical studies verified that dissociation of Gd3+ can be caused by Zn2+ transmetallation 
in vivo. The order of susceptibility of in vivo transmetallation among different chelates is: 
nonionic chelates > ionic chelates > macrocyclic chelate, which is consistent with the 
conclusions from in vitro transmetallation studies.   
 
In Summary 
Chelate stability is a critical factor determining the safety of Gd(III)-based 
contrast agents. It is structural dependent, and can be described thermodynamically or 
kinetically. The thermodynamic approach uses stability constants to describe the 
equilibrium state between chelation and dissociation of the Gd(III) chelates, and thus has 
a practical relevance in terms of formulation where the solutions have enough time to 
equilibrate during the relatively long shelf-life. In comparison, kinetic stability focuses on 
the process of chelate dissociation by describing the rate and mechanisms of the reactions. 
It has more physiological relevance since most clinical Gd(III) chelates have inadequate 
time to equilibrate during their short in vivo retention. The structure and stability 
relationships have been studied in both thermodynamic and kinetic studies.  
Molecular configuration and chelate ionicity are concluded as the two major 
factors determining both the thermodynamic and kinetic stability of Gd(III) chelates. 
Between the two factors, molecular configuration or molecular conformation is of 
primary importance. The macrocylic chelates are generally more stable than the linear 
chelates. The release of Gd3+ from macrocyclic chelates requires breaking of multiple 
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coordination bonds simultaneously, whereas the dissociate takes place more easily for 
linear chelates through sequential bond breaking (18). The ionicity factor, or ligand 
basicity, reflects the strength of the coordination bonds between Gd3+ and its 
corresponding ligand. All clinical Gd(III) chelates contain at least three carboxylic donor 
oxygen atoms for Gd3+ complexing. The nonionic chelates have three carboxylate groups 
and one or two alcoholic or phenol donor groups for Gd3+ complexing, whereas the ionic 
chelates contain more than three carboxylate donor groups. Since ionic bonding requires 
the highest energy to break in comparison to other chelation bonds, the ionic chelates are 
more stable than their nonionic analogues because of their extra ionic bonds. Based on 
the two structural aspects, the order of stability for current clinical Gd(III) agents can be 
deduced as: macrocyclic ionic chelates > macrocyclic nonionic chelates >linear  ionic 
chelates >linear nonionic chelates. In practice, the impact of ionicity is more significant 
among linear chelates than that among macrocyclic chelates in both thermodynamic and 
kinetic studies of Gd(III) chelates. The order of stability among different clinical agents 
were summarized as macrocyclic chelates > ionic linear chelates >> nonionic linear 
chelates.  
 
Relaxivity- Efficacy of Gd(III)-based Contrast Agents 
The efficacy of Gd(III)-based contrast agents is measured in terms of relaxivity. 
According to the Solomon-Bloembergen-Morgan theory, relaxivity is affected by various 
structural factors such as the molecular rotational correlation time, the electron relaxation 
time, and the water residence life time, among which the rotational correlation time is of 
predominant influence (4, 5). The rotational correlation time is longer with decreased 
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molecular tumbling, which can be achieved through enhancement of molecular size and 
solution viscosity (5). While the influence of solution viscosity is limited, the relaxivity 
of Gd(III)-based contrast agents can be significantly increase by enlarging the molecular 
size.  
The influence of molecular size and solution viscosity on relaxivity have been 
demonstrated in the relaxivity studies of clinical agents. All clinical agents are small 
molecules with similar molecular size, resulting in similar relaxivity ranging from 3.0 
mM-1 s-1 to 5.0 mM-1 s-1 when measured in aqueous solutions under the same field 
strength (4, 6, 16). Depending on whether the Gd(III) chelate can reversibly bound to 
plasma proteins after administration, the current clinical agents can be categorized as 
non-protein-binding and protein-binding agents. All marketed agents except MS325 are 
non-protein-binding agents, among which Gd-EOB-DTPA may weakly bind to plasma 
proteins in vivo via its aromatic lipophilic groups. The non-protein-binding agents exhibit 
similar relaxivities in water and in plasma since their molecular size remain the same. 
The plasma relaxivity of these agents can be slightly higher than relaxivities measured in 
water due to higher viscosity of the plasma leading to slightly increased rotational 
correlation time (61). Since the non-protein-binding agents with aromatic groups, 
including Gd-BOPTA and Gd-EOB-DTPA, have slightly higher molecular weight and 
possibly weak plasma protein affinity, they have been shown to exhibit slightly higher 
plasma and water relaxivity than those of the other non-protein-binding agents. In 
comparison, the relaxivity of the protein-binding agent MS325 is dramatically increased 
when exposed in blood where MS325 reversibly binds to plasma proteins, especially 
albumin, resulting in significantly larger molecules with slower rotational correlation 
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time (74, 75).  
In summary, the efficacy of Gd(III) chelates is related to their corresponding 
relaxivity which is predominantly determined by the rotational correlation time of the 
chelate molecule. In comparison, larger molecules of Gd(III) chelates have significantly 
slower molecular rotation in solution. Therefore, they are characterized with dramatically 
higher relaxivity than that of small molecules. This is demonstrated by the significant 
differences in plasma relaxivity between the protein-binding and non-protein-binding 
clinical agents.   
 
Pharmacokinetics and Biodistribution  
The pharmacokinetics and biodistribution of clinical Gd(III)-based contrast agents 
are different depending on different structures. The non-protein-binding agents are small 
molecules characterized with nonspecific extracellular distribution and fast elimination 
post intravenous injection, whereas the protein-binding agent MS325 has limited 
extravasation and comparably slower excretion due to significant increase of molecular 
size through reversible plasma protein binding of the chelate after administration (11, 75, 
76). Renal filtration is the predominant elimination pathway for all clinical agents (11). 
While most agents are exclusively excreted renally, the non-protein-binding agents with 
aromatic groups, including Gd-BOPTA and Gd-EOB-DTPA, can also be cleared via the 
hepatobiliary system (77, 78). As the major elimination route for Gd(III) chelates, the 
pharmacokinetics and biodistribution of clinical agents can be greatly affected when 
patients receiving the contrast agents suffer from impaired kidney function (79-81).        
Based on different elimination pathway, the non-protein-binding agents can be 
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further divided into two groups, the extracellular fluid (ECF) agents that exclusively 
excreted from renal filtration and ECF plus liver agents that can also be eliminated 
hepatically (11). All non-protein-binding agents are small molecules that can rapidly and 
freely distribute to the extracellular space. Their steady-state volume of distribution from 
various pharmacokinetics studies ranged from 210-280 mL/kg, consistent with 
extracellulara distribution (77-80, 82-88). Both ECF and ECF plus liver agents can be 
rapidly eliminated in healthy objects. In comparison to the nonspecific ECF agents, the 
ECF plus liver agents Gd-BOPTA and Gd-EOB-DTPA can be favorably taken up by 
hepatocytes, resulting in relatively better liver enhancement (11). In patients with normal 
renal function, the terminal half life for blood elimination is about 1.5 hours for all ECF 
agents, 1.5–2 hours for Gd-BOPTA, and 1 hour for Gd-EOB-DTPA (78). The slightly 
longer blood retention of Gd-BOPTA may be a result of its weak protein binding, 
whereas significant liver elimination of Gd-EOB-DTPA may lead to its relatively shorter 
blood retention. In moderately renal impaired patients, the half-lives of all non-protein-
binding agents have increased to 4-8 hours (79, 80, 87). In patients with severe renal 
damage, the reported half-lives of these agents were in the range of 18-34 hours, 
approximately 12-22 times higher than that in patients with normal renal function (79, 80, 
87). Significantly prolonged retention of Gd(III) chelates in renal insufficient patients 
may lead to greater in vivo Gd3+ dissociation and deposit, and consequently higher 
possibility of Gd3+ related side effects.   
The protein-binding agent MS325 exhibits distinct pharmacokinetics and 
biodistribution from the non-protein-binding agents due to significant increase of size 
after intravenous injection (89). MS325 has been developed and applied as blood pool 
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imaging agents due to its limited extravasation through reversible plasma protein binding 
(5, 74, 75). Correspondingly, the steady-state volume of distribution for MS325 is 148 ± 
16 mL/kg (89). Renal filtration is the main excretion pathway for MS325. In test subjects 
with normal renal function, its terminal blood half-life is 18.5 hours, considerably higher 
than other non-protein-binding clinical agents (90). Pharmacokinetics studies 
demonstrate that moderate to severe renal impairment resulted in significantly prolonged 
blood retention of MS325 and consequently 2- to 3-fold increase of its terminal half-life 
(90).   
In summary, the pharmacokinetics and biodistribution of clinical Gd(III)-based 
contrast agents vary depending on the structure and size of the chelate, as well as the 
renal functions of patients. Most clinical agents are small molecules with nonspecific 
extracellular distribution and rapid elimination, mainly through renal filtration. One 
exception is the protein-binding agent MS325 that reversibly bound to plasma proteins 
after application, resulting in confined intravascularly distribution, prolonged blood 
retention, and slower excretion. Considerably increased in vivo retention and decreased 
excretion are also discovered in patients with severe renal dysfunction receiving the non-
protein-binding agents due to inefficient elimination. As mentioned in the stability 
section, prolonged in vivo retention may result in elevation of in vivo Gd3+ dissociation 
that consequently leads to increased potential risks for Gd(III) chelates. 
 
Adverse Reaction  
Nephrogenic systemic fibrosis (NSF) is a complex and fatal disorder found mainly 
in patients with marked impairment of renal function receiving Gd(III)-based contrast 
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agents (91-93). It is a fairly new syndrome without thorough understanding, and has not 
been reported until 2000 (94). NSF is characterized by thickening, induration, and 
tightening of the skin with subcutaneous edema, and may lead to joint contractures and 
immobility in severe cases (91, 95). In addition, NSF may also result in complications 
with multiple organs such as the lungs, heart, liver, kidneys, and muscles, and 
consequently causing death through the scarring of body organs (95-98). The severity of 
the disease is patient dependent.  
The cause of NSF was not clear until a report in 2006 suggesting possible 
association between NSF and the administration of Gd(III)-based contrast agents, which 
was further confirmed by various follow-up studies (99, 100) . Despite exposure of 
Gd(III) chelates, other factors such as renal dysfunction in patients also contribute to the 
cause of NSF. Although the mechanism of NSF is still not clear, a correlation between 
NSF lesions and increased Gd3+ dissociation through delayed excretion of the agents was 
indicated in many studies. The majority of NSF cases have been reported with the 
nonionic Gd-DTPA-BMA and Gd-DTPA-BMEA. Other cases have been documented 
with ionic linear agent Gd-DTPA, but not with the macrocyclic agents. Combining the 
fact that NSF has been found only in severe renal impaired patients administered with the 
less stable linear chelates, the epidemiology suggests an important impact of chelate 
stability on the pathogenesis of this condition. The long retention of unstable chelates can 
lead to release of Gd3+, and consequently NSF. Given the severity of NSF and its 
potential association with Gd(III)-based contrast agents, the food and drug administration 
of the USA (FDA) has issued warnings on the labels of current clinical Gd(III)-based 
contrast agents.  
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Limitation of Clinical Agents 
All commercial Gd(III)-based contrast agents except the protein-binding agent 
MS325 are nonspecific small molecular agents with similar relaxivity. The small size of 
these agents rendered short blood retention and rapid elimination of the chelates through 
renal filtration. The fast renal clearance of the clinical agents minimizes the potential in 
vivo release of Gd3+ that can consequently result in long-term Gd(III) tissue deposit, and 
thus assures relatively good safety profile of these agents in clinical application (6). On 
the other hand, the nonspecificity and short blood retention of the non-protein-binding 
small molecular agents provide low tissue discrimination and limited time window 
(approximately 5 minutes) for effective MR diagnosis of the more challenging tasks such 
as early detection of cardiovascular dysfunction and cancer (5).  
 
Macromolecular Gd(III)-based Contrast Agents 
Both natural and synthetic polymeric systems have been widely used in 
biomedical applications as carriers for various drugs and targeting ligands (101). The 
diverse functionalities of marcomolecules make them suitable candidates for MR contrast 
agents as well. In comparison to small molecular Gd(III) chelates, macromolecular agents 
have considerably slower molecular tumbling due to dramatic increase of size, resulting 
in superior relaxivity (5, 7) . As demonstrated with the protein-binding agent MS325, the 
increase of size can also lead to limited extravasation and prolonged blood retention, 
providing blood pool imaging with longer diagnostic window (75, 102, 103). In addition, 
macromolecules can carry a large payload of Gd(III) chelates and targeting ligands, 
enabling tissue-specific imaging with lower dose. The combined properties of high 
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relaxivity, long blood retention, and better tissue specificity make maromolecular 
Gd(III)-based contrast agents promising for a wider range of imaging challenges such as 
MR angiography and tumor prognosis (8-10, 104, 105).  
A wide range of Gd(III)-based marcomolecuar MR contrast agents has been 
developed such as linear polymers, dendrimers, liposomes, micelles, and nanoparticles 
(101, 106). These macromolecular contrast agents generally have molecular weights over 
20 kDa and hydrodynamic diameter over 1-2 nm. The pharmacokinetics and 
biodistrubution profile vary among different macromolecular agents as their size and 
ligand attachments change.  
 
Different Types of Macromolecular Gd(III)-based Contrast Agents 
Linear Polymeric-based Gd(III) Contrast Agents  
 Early research utilized natural linear polymers such as the plasma protein, serum 
albumin, as the macromolecular platform for Gd(III) labling (107, 108). While proteins 
are abundantly available with high homogeneity, they are associated with problems such 
as limited Gd(III) loading sites, immunogenic effects, and insufficient clearance (7, 109). 
To overcome these problems, instead of chemically attaching Gd(III) chelates to proteins, 
the protein-binding agent MS325 have been developed as small molecules that can 
reversibly bound with plasma proteins after application for clinical blood pool imaging 
(74, 75, 102). In comparison to proteins, synthetic linear polymers are more versatile 
carriers for Gd(III)-based contrast agents. Various linear polymer-based macromolecular 
Gd(III) contrast agents, such as polysaccharides, polyethylene glycol (PEG), and 
different polyamino acids agents, have been developed and evaluated (80, 110-113).  
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Polysaccharides provide biocompatible linear platforms capable of carrying high 
payloads of Gd(III) chelates, among which dextran was first applied as macromolecular 
Gd(III) contrast agent (114, 115). It has been widely used as macromolecular delivery 
systems for various drugs due to its good water solubility and biodegradability (116). In 
one study, a 165 kDa dextran was shown to conjugate as many as 187 Gd(III) per 
molecule, demonstrating its high loading capacity for Gd(III) chelates (115). The high 
payloads of Gd(III) and large size of dextran-based Gd(III) agents should result in 
significantly increased relaxivity than that of the small molecular clinical agents (3.3 
mM-1 s-1 at 1.5 T, 37 °C). This was verified in a separate study where the T1 relaxivity of 
a 75 kDa dextran-Gd-DTPA conjugate was 10.5 mM-1s-1 (0.25 T, 37 °C) (117). However, 
dextran-based contrast agents have a high degree of polydispersity which makes the 
preparation of identical formulations difficult. Therefore, it may have inconsistent in vivo 
distribution and pharmacokinetics due to the differences between batches (118, 119). 
Other polysaccharides such as inulin, hydroxyehyl starch, and chitosan oligosaccharides 
have been investigated as carriers for Gd(III)-based contrast agents (120-122). In 
comparison with small molecular Gd(III) chelates, the polysaccharides agents all showed 
significantly improved image contrast due to enhanced T1 relaxivity, and dramatically 
prolonged in vivo retention up to 7 days after administration due to slow clearance.  
 The potential of PEG Gd(III) conjugates as macromolecular contrast agents have 
been explored (123). Similar to polysaccharides, PEG has good biocompatibility and 
hydrophilicity for biomedical application. In addition, the narrow polydispersity of PEG 
facilitates repetition of identical formulations. A family of PEG diamines-Gd-DTPA 
complex with a wide range of molecular weights and linear or globular structures have 
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been developed and compared (123). These compounds were synthesized with molecular 
weights under 50 kDa. The studies showed that the blood retention of PEG Gd(III) 
conjugates lengthened as molecular weight of the polymers increased, which indicated 
the impact of molecular size on the pharmacokinetics of macromolecular contrast agents. 
Moreover, the studies also demonstrated the influence of polymeric rigidity on relaxivity 
as the globular PEG Gd(III) conjugates showed higher relaxivity than its linear polymer 
counterparts. It was proposed that the higher rigidity of globular structure led to increased 
water exchange rate and viscosity, both contributing to enhancement of relaxivity. 
 Polyamino acids, such as polyglutamic acid (PGA) and polylysine (PLL), have 
been investigated as another suitable polymeric Gd(III) loading platform (80, 110-112). 
Besides superior biocompatibility, both PGA and PLL are flexible with molecular 
weights. They have highly modifiable side groups for attachment of Gd(III) chelates and 
various targeting ligands. For instance, our group has developed PGA-1,6-
hexanediamine-Gd-DOTA complex with molecular weights ranging from 28 kDa to 87 
kDa (124). Size-dependent relaxivity and contrast enhancement was demonstrated in this 
study. Cancer-specific contrast enhancement was also observed with the PGA Gd(III) 
conjugate, indicating passive cancer targeting of the agent. In another study, PLL-Gd-
DTPA  conjugate was synthesized with 3-fold increase of relaxivity in comparison to Gd-
DTPA (125). The PLL conjugate was further modified through PEGylation to achieve 
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Dendrimer-based Gd(III) Contrast Agents 
 Dendrimers have become popular drug carrier systems due to their defined 
structure and the availability of multivalent surface groups (127, 128). They have 
globular structures consisting of a core, an inferior section, and an outer surface. The 
multivalent groups on the outer surface enable attachment of different functional groups, 
thus facilitating modifications for various biomedical applications (128). For Gd(III)-
based contrast agents, the large amount of surface groups such as amines and carboxylic 
acids not only provides high Gd(III) loading capacity, but also facilitates conjugation of 
various targeting groups,  rendering dendrimer-based Gd(III) contrast agents promising in 
molecular imaging (129).  
The size of dendrimers is an important parameter affecting the relaxivity, 
solubility, pharmacokinetics, and biodistribution of dendrimer-based Gd(III) contrast 
agents (129). As dendrimer size increases after each generation, the surface functional 
groups increase, resulting in higher Gd(III) loading. For instance, Gd(III) loading 
increased from 96 Gd(III) per molecule for a generation 5 (G5) polyamidoamine 
(PAMAM) dendrimer to 1860 (III) per molecule for a G10 PAMAM dendrimer (130). As 
more Gd(III) ions attach to each molecule, the MR signal is enhanced. The increase of 
size also contributes to enhancement of relaxivity due to slower molecular tumbling and 
increased Gd(III) loading. This was demonstrated in one study where the relaxivity 
increased from 20 mM-1 sec-1 for a G2 PAMAM Gd(III) conjugate to 28 mM-1 sec-1 for a 
G4 PAMAM Gd(III) conjugate (131). In comparison, another study reported the 
relaxivity for a G10 PAMA Gd(III) conjugate to be as high as 36 mM-1 sec-1 (130). In 
terms of pharmacokinetics, the excretion route differs with increase of size. Smaller 
                                                                                                                                             	  
	  
39 
dendrimers are rapidly cleared through renal filtration and larger dendrimers tend to 
accumulate and are eliminated through liver (131). Besides dendrimer size, the 
pharmacokinetics of dendritic Gd(III) conjugate is also influenced by the core and 
interior section of dendrimers. It has been shown that increased hydrophilicity and 
flexibility of the core and interior facilitate renal clearance while increased 
hydrophobicity and rigidity  of the inner structures may lead to longer blood retention and 
higher liver accumulation (132).   
 Targeted dendritic Gd(III) contrast agents have been developed for tissue-specific 
imaging (118, 133). Although the total relaxation per molecule for G5 and lower 
generation dendritic Gd(III) conjugates are beyond the expected threshold for molecular 
imaging, it is hypothesized that signal amplification of targeted tissues can be achieved 
through receptor-mediated internalization and recycling of targeted dendritic Gd(III) 
conjugates (134). For instance, folate were attached to a G4 and a G5 PAMAM Gd(III) 
agent to image tumors expressing high density of folate receptors (134, 135). Significant 
tumor contrast was observed in comparison to that of nontargeted dendritic Gd(III) 
conjugate and free Gd-DTPA in this study.   
 Although higher generation dendrimers provide higher Gd(III) loading and more 
versatile modifications, they are more complicated to prepare and have lower solubility. 
Dendritic nanocluster (DNC) systems have recently been developed to conquer these 
problems (136). DNCs are nanoparticles formed by crosslinking individual Gd(III)-
labeled dendrimers, through which the highly soluble and easily synthesized lower 
generation dendrimers can be used to achieve high Gd(III) loading and relaxivity. It has 
been shown that 300,000 Gd(III) can be loaded to a 150 nm DNC, resulting in relaxivity 
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high enough for targeted molecular imaging (136). 
 
Nanoparticle-based Gd(III) Contrast Agents 
 Liposomes are synthetic spherical vesicles with lipid bilayer membranes that have 
been widely used as macromolecular vehicles for various nutrients and pharmaceutical 
drugs (137). Its potential to carry Gd(III) chelates has been investigated through either 
encapsulating the chelates within liposomal vesicles or immobilizing the chelates on its 
surface (138-140). In comparison, liposomal encapsulation provides higher Gd(III) 
payloads than that from surface conjugation. However, the liposomes with encapsulated 
Gd(III) chelates are generally characterized with low relaxivity as its lipid bilayers limit 
the water accessibility of the encapsulated Gd(III) (141). Liposomes with surface-bound 
Gd(III) chelates experience better water exposure that contributes to improved relaxivity 
(139). The limitation of encapsulated liposomal-based Gd(III) contrast agents has 
recently been addressed through development of paramagnetic porous polymersomes 
with improved water permeability (142). In comparison to liposomes, more versatile 
structure and functionality can be achieved from polymersomes since they are easier to 
manipulate through polymer selection and design (143, 144). For polymersome 
encapsulated Gd(III) contrast agents, membrane permeability for water is achieved by 
introducing pores into the vesicle bilayer through two different approaches (145, 146). In 
both preparation methods, Gd(III) chelates are attached to dendrimers before 
encapsulation to prevent possible leaking of small molecular Gd(III) chelates from the 
porous vesicles. The resulting relaxivity is considerably higher in comparison to the 
liposomal encapsulated Gd(III) chelates.   
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Similar to liposomes, micellar-based Gd(III) contrast agents have been developed 
and evaluated as highly paramagnetic nanoparticle contrast agents (147-150). The 
micellar particles are synthesized through self-aggregation of Gd(III)-labeled amphiphilic 
compounds. Their hydrophobic parts orient towards the core of nanoparticle and the 
Gd(III)-labeled hydrophilic moieties are exposed to the aqueous solvent (147). It has 
been shown in one study that Gd(III)-labeled micelles formed in this approach exhibited 
relaxivity of 18.03 mM-1s-1 (20 MHz, 37 °C) (147). In addition to pre-attaching Gd(III) 
chelates to amphipilic units before micellar formation, Gd(III) loading can also be 
accomplished vice versa through postlabeling of preformed micelles (151). It has been 
shown that micellar Gd(III) contrast agents achieved through both methods exhibit 
similar relaxivities, which can be further improved through manipulation of the micellar 
structure such as cholesterol incorporation or structure modification of the conjugated 
Gd(III) chelates (148-150).  
Another kind of nanoparticle-based Gd(III) contrast agents involves the 
application of perfluorocarbon (PFC) nanoemulsions. In this case, liquid PFC core is 
surrounded by a lipid monolayer that can be functionalized to contain various agents for 
imaging or therapeutic purposes (152). The Gd(III)-labeled PFC nanoemulsions requires 
a large amount of lipid Gd(III) chelates to stabilize the system which also result in to high 
Gd(III) loading. In one study, a loading capacity of up to 100,000 Gd(III) per PFC 
particle was demonstrated, showing relaxivity of 17.7 mM-1s-1 (1.5 T, 37 °C) (153). 
Higher relaxivity can be achieved through further modification of the nanoemulsion or 
the structure of lipid Gd(III) chelates (154-158). In addition, targeted Gd(III)-labeled PFC 
nanoemulsions can be synthesized through incorporation of various targeting ligands into 
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the PFC nanoemulsion systems. The targeted diagnostic agents are promising in areas 
such as tumor and atherosclerotic plaque MR imaging (155-157).  
 
Safety Concerns of Gd(III)-based Macromolecular Contrast Agents 
Although macromolecular Gd(III)-based contrast agents are promising in blood 
pool and tumor imaging, their clinical translation has been hindered due to several factors 
such as difficult quality control, lack of scalability, unfavorable pharmacokinetics, and 
inefficient elimination. Among them, the potential safety issues associated with slow 
excretion of macromolecular agents are the primary concern (11, 159). Since renal 
filtration is the primary elimination route for Gd(III)-based contrast agents, inefficient 
renal clearance can result in prolonged retention of Gd(III) chelates, and consequently 
increases the chance of in vivo Gd3+ release. The risk associated with long-term Gd(III) 
retention has been clinically demonstrated in the cases of severely renal impaired patients 
who developed NSF after administration of linear small molecular Gd(III) agents (92, 99). 
In comparison to small molecular clinical Gd(III) agents, the experimental 
macromolecular-based Gd(III) contrast agents tend to have significantly longer retentions 
even in healthy animals due to their relatively large sizes that prevent efficient renal 
clearance (11). The retention level and patterns of macromolecular Gd(III) agents on 
healthy objects, as shown in some studies, were similar to that of the linear clinical agents 
on renal insufficient patient (160). This indicated the potential risk of macromolecular 
agents. Therefore, to facilitate the clinical translation of macromolecular agents, efforts 
should be focused on improving the elimination of macromolecular agents while 
retaining their advantage in blood pool and tumor imaging.  




The current clinical Gd(III)-based contrast agents are nonspecific small molecular 
monomeric Gd(III) chelates providing a limited diagnostic window for MR imaging (6). 
Over the past decade, various types of macromolecular Gd(III)-based contrast agents 
have been developed as MR imaging agents with higher potency for the more challenging 
diagnostic tasks such as early detection of tumor and angiogenesis staging (118, 159). In 
comparison to current clinical agents, macromolecular Gd(III)-based contrast agents 
exhibit higher relaxivity due to slower molecular tumbling and large Gd(III) payloads. 
Also, they provide longer diagnostic windows due to their prolonged in vivo retention. 
Moreover, the macromolecular agents, with versatile compositions, can be designed to 
achieve multiple functions besides diagnosis, such as targeting and treatment. Therefore, 
they are promising for clinical applications. However, the dramatic increase of molecular 
size has created potentially high safety issues due to inefficient excretion of the 
macromolecular agents, hindering their further development in clinical applications (11). 
To address this problem, a balance should be maintained between efficacy and safety 
during the design of macromolecular Gd(III)-based contrast agents in order to minimize 
the potential risks while retaining the advantages of macromolecular contrast agents.  
 
Biodegradable Polymeric Gd(III)-based Contrast Agents 
In our previous studies, polymeric contrast agents with efficient biodegradability 
were designed to alleviate the safety concerns associated with long-term in vivo 
deposition of macromolecular Gd(III)-based contrast agents while retaining their 
advantages in MR imaging (124, 161-164). The biodegradable polymeric contrast agents 
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were designed based on in vivo degradability of disulfide bonds (161). Two types of 
biodegradable polymeric Gd(III) complex systems have been developed through different 
disulfide incorporation approaches: the backbone-incorporation method which results in 
polydisulfides and the side-chain-incorporation approach that leads to disulfide-grafted 
polymers (163, 165) (Figure 1.3). The polydisulfides and disulfide-grafted poly(L-
glutamic acid) (PGA) are derived from Gd-DTPA and Gd-DOTA, respectively. The 
safety and effectiveness of the two biodegradable imaging systems were systemically 
evaluated, and compared in our preliminary studies.  
 
Synthesis and Characterization of the Disulfide-based Contrast Agents 
The preparation of the disulfide-based biodegradable polymeric Gd(III) contrast 
agents can be summarized into two steps: 1) synthesis of polymeric ligands, including 

























Figure 1.3. Structure design of disulfide-based contrast agents  
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Gd3+ (164). Chemical structure from each synthetic step was verified by H1-NMR and 
mass spectroscopy. The molecular weight, Gd(III) content, and relaxivity of the 
biodegradable contrast agents were determined as primary standards for the selection of 
suitable synthetic contrast agents for in vivo studies.  
The polydisulfides Gd-DTPA were synthesized by copolymerization of disulfide-
contained monomers and DTPA dianhydride (162). The ligand PGA-cystamine-DOTA, 
was obtained by conjugating cystamine-DOTA to the active ester of PGA (165). For the 
polydisulfide system, the impact of side chain structure on degradability was evaluated 
through comparison of three different polydisulfides with different side chain structures 
around the disulfide bonds: the polydisulfide with no side chains (Gd-DTPA cystamine 
copolymer, GDCC), with neutral side chains (Gd-DTPA cystine diethyl ester copolymer, 
GDCEP), and with negatively-charged side chains (Gd-DTPA cystine copolymer, 
GDCP). In addition, a nondegradable counterpart of GDCC, Gd-DTPA 1,6-
hexanediamine copolymer (GDHC), which has no disulfide bonds, was synthesized for 
comparison purposes (166, 167). Similarly, a nondegradable control of PGA-cystamine-
Gd-DOTA was also synthesized using the nondegradable spacer, 1,6-hexanediamine 
(168).  
The average molecular weight of the synthetic polymeric contrast agents was 
determined by size exclusion chromatography (SEC). For macromolecular contrast 
agents, molecular size is an important factor affecting their elimination efficiency and 
tumor-diagnosing efficacy (105, 118, 169). The increase of size often results in improved 
relaxivity and tumor diagnosing effect, but can lead to prolonged retention with greater 
safety concerns (162, 166). Therefore, an ideal molecular weight of a biodegradable 
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system needs to be determined to assure proper balance between efficacy and safety. In 
our study, the polydisulfide Gd-DTPA and PGA-cystamine-Gd-DOTA with similar 
molecular weight (Mn≈60 kDa) were first synthesized and evaluated (163, 165). While 
both contrast agents showed similar tumor diagnosing effect, the polydisulfide Gd-DTPA 
showed better excretion post administration. This indicated it has better in vivo 
degradability and are therefore a safer choice than PGA-cystamine-Gd-DOTA for clinical 
application. Additional studies were then carried out to choose the optimal molecular 
weight for polydisulfides Gd-DTPA (162, 166, 167, 170). Polydisulfides with different 
molecular weight were obtained by adjusting the temperature, time, and solvent systems 
of the polymerization reactions. According to our study, polydisulfides Gd-DTPA 
ranging from 20-40 kD were optimal candidates for clinical application due to their good 
tumor diagnosis efficacy and comparably low in vivo accumulation.  
 
Verification of Degradation  
The degradation of the disulfide-based polymeric contrast agents was verified by 
in vitro incubation of the agents with aqueous solutions (pH 7.4) of free thiols (cysteine 
in our experiments) (163, 165). For polydisulfides Gd-DTPA, the influence of side chain 
structure around disulfide bonds were evaluated by comparing the degradation of GDCC, 
GDCEP, and GDCP with similar molecular weight (162, 166, 167, 170). The results 
demonstrated significantly different degradation profiles among the three structures. 
When incubating with plasma concentration of cystine solution (15 µM), GDCP showed 
no change in molecular weight over time; GDCEP showed comparably faster degradation, 
with a decrease of 6 %, 11 %, and 24 % of molecular weight at 5, 15, and 60 minutes 
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during incubation; GDCC demonstrated the most efficient degradation with 28 %, 33 %, 
and 50 % molecular weight decrease at 5, 15, and 60 minutes during incubation (163, 166, 
167). The degradation of GDCP and GDCEP increased considerably when the 
concentration of cysteine was 10-fold higher (166). The slower degradation of GDCEP 
and GDCP illustrated the influence of side chain structures around the disulfide bonds on 
degradability of polydisulfides. For GDCEP, its relatively long neutral side chains (ethyl 
ester) may hinder the approach of free thiols to the disulfide bonds and result in slower 
degradation. For GDCP, the attack of cysteine may be restrained by electrostatic 
repulsion due to the negative charges of the carboxylic groups on both cysteine and the 
side chains of GDCP. 
In comparison to GDCC, the PGA-disulfide grafted system showed relatively 
slower in vitro degradation, which was only observed with cysteine incubation at higher 
concentrations (100 µM) (161). The grafted polymeric structure of PGA-cystamine-Gd-
DOTA and the steric hindrance of the DOTA side chain may confine the accessibility of  
disulfide bonds in solution and lead to inefficient degradation of the polymer.  
The results of in vitro degradation study were consistent with in vivo observation, 
both showing more efficient degradation of the polydisulfides over the PGA-disulfide 
system (161, 164, 166, 171). For the polydisulfide system, degradation can be greatly 
affected by side chain strucutres around the disulfide bonds. Modificaion such as increase 
of side chain bulkiness or introduction of negatively charged side chains can lead to 
slower degradation of the polydisulfides. Overall, the degradability of disulfide-based 
polymeric systems depends mainly on the availability of highly accessible disulfide 
bonds in solution. In our case, the linear polydisulfide structure provides more spatial 
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freedom and thus higher accessibility of the disulfide bonds than that of the grafted 
polymeric disulfide structure. This effect rendered linear polydisulfide to be the better 
structure for further clinical development.   
 
 In Vivo MR Imaging  
The tumor diagnosing efficacy of GDCC and PGA-disulfide-Gd-DOTA were 
evaluated on mice tumor xenograft models, in comparison with the clinical agent 
Ominiscan® (164, 165, 172). The MR studies were performed under similar conditions 
with both agents (164). The results showed that the tumor and blood pool enhancing 
effects of both disulfide incorporated polymers were between the efficacy of Ominiscan® 
and their respective nondegradable controls. Both polymers demonstrated improved 
diagnosing effect in comparison with the small molecular clinical agents (161, 165). 
Further analysis of in vivo MR imaging revealed longer blood retention of PGA-
disulfide-Gd-DOTA than that of GDCC. The contrast enhancement of GDCC was close 
to baseline level after 30 minutes post injection, while significant contrast enhancement 
was still observable for the PGA-disulfide-grafted polymer up to 4 hours post injection. 
This can be explained by the slower in vivo degradation of the grafted polymeric system.   
   
Long-term Accumulation Study  
Evaluation of long-term tissue accumulation was performed among Ominiscan®, 
GDCC (18 kD), GDCC (60 kD), GDCEP, GDCP, and GDCH, as well as between PGA-
cystamin-Gd-DOTA and its nondegradable counterpart, in different studies (161, 166, 
167, 173). In all studies, the Gd(III)-based contrast agents were intravenously injected to 
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Sprague-Dawley rats at the standard clinical dose of 1.0 mmol-Gd/kg. The rats were kept 
for 10 days and then sacrificed to collect various tissues, including heart, lung, spleen, 
kidney, muscle, femur, and liver. The remaining Gd(III) content in each organ was 
measured using the inductively coupled plasma optical emission spectrometry (ICP-OES). 
The results showed that the order of tissue accumulation was: liver > muscle > kidney > 
femur > spleen > heart≈lung for all the polymeric agents, while negligible residues of 
Gd(III) was detected with the clinical agent. Although both types of biodegradable 
polymeric agents had significant decrease of tissue accumulation in comparison with 
their nondegradable controls, the disulfide-grafted agents exhibited significantly higher 
liver and spleen accumulation than the polydisulfides Gd-DTPA. Among the 
polydisulfides, GDCC with lower molecular weight (18 kD) showed minimal tissue 
accumulation, which was comparable to that of the clinical agent Omniscan®. Overall, 
the long-term accumulation studies showed that both biodegradable disulfide-based 
polymeric systems can greatly reduce long-term Gd(III) tissue deposit in comparison 
with the nondegradable polymers. However, the level of residual Gd(III) was still higher 
for most biodegradable systems than that of the clinical agents (173). Between the two 
disulfide-based polymeric systems, the polydisulfides were more efficiently eliminated 
than the disulfide-grafted polymers. It resulted in considerably less residual Gd(III) 10 
days after administration of the agents. This indicated that the polydisulfides were the 








GDCC (20-40 kD) was the most clinically promising biodegradable contrast agent 
we have developed. However, it was facing another potential safety issue due to the less 
stable linear chelate Gd-DTPA on which the polydisulfide agent was based. As 
mentioned in the previous section, low kinetic stability of the linear chelates, especially 
the nonionic linear chelates, could result in the release of free Gd3+ ions through 
transmetallation with endogenous metal ions such as Zn2+, Cu2+, and Ca2+ (17, 24). This 
risk of Gd3+ release increased with inefficient elimination of the agents, in the case of 
patients with severe renal impairment receiving clinical linear agents (81, 91) or in the 
case of patients with normal renal function receiving nondegradable macromolecular 
contrast agents (11). Although the biodegradable polymeric systems can significantly 
improve the elimination efficiency, they still lead to relatively higher long-term Gd(III) 
residues in comparison with that of the clinical agents. As a result, the nonionic linear 
chelate-based polydisulfide GDCC (20-40 kD) may result in greater loss of Gd3+ in 
comparison with the small molecular linear agents due to its relatively longer in vivo 
retention. To evaluate the extent of transmetallation of GDCC (20-40 kD), in vitro and in 
vivo studies have been carried out to understand the kinetic stability of GDCC in 
comparison with the clinical contrast agents: Ominiscan® (linear ionic), MultiHance® 
(linear nonionic), and ProHance® (macrocyclic) (174).  
The transmetallation of GDCC was first verified through in vitro incubation study 
using phosphate buffered solutions (PBS) with or without the existence of endogenous 
metal ions under physiological pH and temperature (173). The results showed that 
approximately 15 % of Gd(III) was lost within 45 minutes post incubation with 
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endogenous metal ions, whereas no change in Gd(III) content was observed in negative 
control solution, indicating the occurrence of transmetallation for GDCC. To better 
simulate in vivo transmetallation, further in vitro assessment of transmetallation was 
carried out through incubation studies using fresh rat plasma for GDCC (31 kD) and 
different clinical agents as the majority plasma metal species are protein-bound instead of 
free ions. After incubation, ultrafiltration was used to separate the protein-bound metal 
species and the exogenous polymeric ligand-bound metal species based on their size 
differences. The measurement was carried out by incubation of plasma concentrations of 
various Gd(III) agents with fresh rat plasma at room temperature for 2 hours. The 
different molecular components of the plasma mixture was then separated by 
ultrafiltration and measured using ICP-OES. The degree of transmetallation was 
calculated based on the proportion of ligand bound metals versus protein bound metals. 
Our results showed that the transmetallation happened mainly between plasma Zn(II) and 
the contrast agents. The order of transmetallation of the tested agents with plasma Zn(II) 
was: Omniscan (linear nonionic) > MultiHance (linear ionic) ≈ GDCC > ProHance 
(macrocyclic).  
In vivo transmetallation was assessed through analysis of metal metabolites in rat 
urines after administration of Gd(III)-based agents (173). In this study, the animals were 
injected with various Gd(III)-based agents at the clinical dose of 0.1 mmol Gd/kg, 
followed by collection of urine samples at 8 hours and 24 hours post injection. Urine 
samples collected 12 hours before administration of Gd(III) agents were used as negative 
controls. The collected urine samples were processed and analyzed to calculate 
transmetallation. Similar to what was shown from in vitro studies, in vivo analysis also 
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revealed Zn(II) as the major metal species responsible for the loss of Gd(III) from its 
ligand through transmetallation. Between the two time points, significant transmetallation 
was only observed at 8 hours post injection at the order of Ominiscan (linear nonionic) > 
MultiHance (linear ionic) > GDCC > ProHance (macrocyclic).  
In summary, both in vitro and in vivo transmetallation study showed clear 
correlations between chelate structure and kinetic stability. Similar order of stability was 
observed among the four agents tested in both studies: macrocyclic chelate 
(ProHance®) > linear ionic chelate (MultiHance®) ≈ GDCC (31 kD) > linear nonionic 
chelate (Omniscan®). Although GDCC is based on linear nonionic chelates, the 
polymeric structure itself may produce steric hindrance against transmetallation with the 
endogenous Zn(II), making it more stable than the small molecular nonionic chelates. 
However, the stability of GDCC was still relatively low in comparison to the macrocyclic 
agents. Given its comparably higher in vivo retention than that of the small molecular 
agents (173), GDCC is still suffering from higher risks associated with long-term deposit 
and release of Gd3+, which hinders its further clinical translation.   
 
Statement of Problem 
Macromolecular Gd(III)-based contrast agents have shown promising potential in 
the more challenging diagnosis areas such as tumor detection and staging. However, they 
are confined by safety issues associated with inefficient eliminations. To improve the 
elimination efficiency while pertaining the advantages of macromolecular agents, we 
have developed disulfide-based biodegradable polymeric Gd(III) contrast agents with 
efficient elimination and relatively good tumor diagnosing efficacy. However, the 
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previous developed polydisulfides were based on the kinetically labile nonionic linear 
chelates which can possibly trigger severe side effects (81, 99). To further improve the 
safety profile of polydisulfide based MR contrast agents, two alternative strategies were 
proposed and investigated in the following chapters: 1) development of polydisulfide 
based non-Gd(III) MR contrast agents; 2) replacement of the linear chelates with the 
more stable macrocyclic chelates on the polydisulfide structure.   
   
Manganese-based Biodegradable MR Contrast Agent 
Paramagnetic manganese(II) chelates or compounds are an alternative class of MRI 
contrast agents (12). As an endogenous metal, the manganese-based contrast agents 
exhibit unique biodistribution pattern and effective contrast enhancement in the 
myocardium, liver, and brain (175, 176). The main limitation of the manganese-based 
contrast agents is their relatively low relaxivities. Because of this, an increased dose is 
often needed to generate sufficient contrast enhancement, which may lead to unexpected 
toxic side effects. Chemical modifications of manganese-based contrast agents may result 
in more effective nongadolinium contrast agents by improving their relaxivities and 
optimizing their pharmacokinetics and biodistribution.   
 
Project Aims 
Incorporation of manganese(II) into polydisulfides may result in effective 
manganese-based MRI contrast agents with improved contrast enhancement at a 
relatively low dose.  In this study, two polydisulfide Mn(II) complexes were synthesized 
and evaluated as non-gadolinium biodegradable macromolecular MRI contrast agents.  In 
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vivo contrast enhancement of the agents were evaluated on mice bearing MDA-MB-231 
breast cancer xenografts. 
 
The Polydisulfide Biodegradable System Based on Macrocyclic Gd(III) Chelates 
Macromolecular Gd(III)-based contrast agents are effective for contrast-enhanced 
blood pool and cancer MRI in preclinical studies (9).  However, their clinical applications 
are impeded by potential safety concerns associated with slow excretion and prolonged 
retention of these agents in the body. To improve the elimination efficiency of 
macromolecular MR contrast agents, we have designed and developed biodegradable 
polymeric Gd(III) contrast agents based on polydisulfide Gd(III) complexes. The 
previous polydisulfide agents were based on the less stable nonionic linear Gd(III) 
chelates, causing safety concerns for further clinical development. In this study, we 
designed and synthesized a new generation of polydisulfide Gd(III) complexes based on 




In this study, we have designed and synthesized two new polydisulfides based on 
the macrocyclic Gd chelates as biodegradable blood pool agents with high overall kinetic 
inertness. The work includes: 1) synthesis and characterization of the new agent; 2) 
demonstration of degradation mechanism in vitro; 3) evaluation of the kinetic stability in 
vitro; 4) evaluation of efficacy in MR blood pool imaging and cancer diagnosis; 5) 
pharmacokinetics study; 6) biodistribution study; 7) metabolic study of transmetallation. 
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CHAPTER 2  
 
POLYDISULFIDE MANGANESE(II) COMPLEXES AS NON-GADOLINIUM 
BIODEGRADABLE MACROMOLECULAR  
MRI CONTRAST AGENTS 
 
Introduction 
Magnetic resonance imaging is a clinical diagnostic imaging modality 
advantageous in providing images of soft tissues in high resolution with no ionizing 
radiation. Paramagnetic chelates and ferromagnetic nanoparticles are developed as MRI 
contrast agents to effectively improve tissue contrast by altering the relaxation rates of 
water protons in the tissue of interest. Currently, the most commonly used clinical 
contrast agents are stable Gd(III) chelates, including Gd-DTPA (Magnevist®), Gd-
DOTA (Dotaram®), Gd(DTPA-BMA) (Omniscan®), Gd(DOTA-HP) (ProHance®) and 
Gd(BOPTA) (MultiHance®) (1, 2). Recently, the Gd(III)-based contrast agents have 
been found in association with nephrogenic systemic fibrosis (NSF), a severe disease 
affecting a small percentage of the patients with kidney deficiency who had a history of 
the exposure to Gd(III)-based contrast agents (2-4). Although the cause for NSF is still 
unclear, the design and development of effective non-gadolinium contrast agents with 
lower toxicity may alleviate the safety concerns over MRI contrast agents.
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Paramagnetic manganese(II) chelates or compounds are an alternative class of 
MRI contrast agents. As an endogenous metal, the manganese based contrast agents 
exhibit unique biodistribution pattern and effective contrast enhancement in the 
myocardium, liver and brain (5, 6). Currently, two manganese based contrast agents, an 
oral formulation of MnCl2 (Lumanhance) and an intravenous formulation of MnDPDP 
(Mangafordipir triosodium), are available for clinical application (5). The main limitation 
of manganese based contrast agents is their relatively low relaxivities. Because of this, an 
increased dose is often needed to generate sufficient contrast enhancement. However, a 
high dose of manganese based contrast agents may lead to unexpected toxic side effects.  
Chemical modifications of manganese based contrast agents may result in more effective 
non-gadolinium contrast agents by improving their relaxivities and optimizing their 
pharmacokinetics and biodistribution (7-11).   
Recently, we have designed and developed polydisulfide Gd(III) chelates as 
biodegradable macromolecular MRI contrast agents (12-14) to address the safety issue 
associated with long accumulation of macromolecular contrast agents. The polydisulfide 
Gd(III) chelates have shown increased relaxivity, prolonged circulation and preferential 
tumor accumulation as compared to small molecular Gd(III) chelates (15). These 
biodegradable macromolecular contrast agents were degraded into oligomeric Gd(III) 
chelates, which can be rapidly excreted via renal filtration after imaging (16). 
Incorporation of Mn(II) into polydisulfides may result in effective manganese-based 
contrast agents with improved contrast enhancement at a relatively low dose. In this 
study, two polydisulfide Mn(II) complexes were synthesized and evaluated as 
nongadolinium biodegradable macromolecular MRI contrast agents. In vivo contrast 
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enhancement of the agents were evaluated in female nu/nu athymic mice bearing MDA-
MB-231 breast cancer xenografts. 
 
Experimental Section 
Synthesis of Contrast Agents   
The biodegradable macromolecular contrast agents, Mn-DTPA cystamine 
copolymers (MDCC) and Mn-EDTA cystamine copolymers (MECC), were synthesized 
by complexing Mn(II) with its polymeric ligand DTPA cystamine copolymers (DCC) and 
EDTA cystamine copolymers (ECC), respectively. The polymeric ligand DTPA 
cystamine copolymers were prepared by copolymerizing DTPA dianhydride (5.0 mmol, 
1.79 g) and cystamine (5.0 mmol, 1.13 g) as previously reported ((12, 14)). The ligand 
EDTA cystamine copolymers (ECC) were obtained similarly by copolymerizing EDTA 
dianhydride (5.0 mmol, 1.12g) and cystamine (5.0 mmol, 1.13g).  Mn(OAc)2 (1.5 mmol, 
0.26 g) was then complexed with DTPA cystamine copolymers (1.0 mmol, 0.51 g) or 
EDTA cystamine copolymers (1.0 mmol, 0.41 g) in deionized water at room temperature 
for 2.5 hours. The final product, Mn-DTPA cystamine copolymers and Mn-EDTA 
cystamine copolymers, were purified by dialysis against de-ionized water using a 10 kDa 
molecular-weight-cut-off membrane, and then lyophilized.  The molecular weight of Mn-
DTPA cystamine copolymers was determined by size exclusion chromatography (SEC) 
on an AKTA FPLC system with a Superose™ 6 column (GE Healthcare Life Sciences). 
The column was calibrated using water soluble poly[N-(2-hydroxylpropyl)-
methacrylamide] (HPMA) standards with a series of different molecular weight (Mn = 32, 
47, 80 and 148 kDa). The structures of the polymeric ligands, DTPA cystamine 
copolymers and EDTA cystamine copolymers, were verified using 1H-NMR and FT-IR. 
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The manganese content in the copolymers was measured by inductively coupled plasma 
atomic emission spectroscopy (ICP-OES). The yield is approximately 45% for both Mn-
DTPA cystamine copolymers and Mn-EDTA cystamine copolymers after purification.  
 
Kinetic Stability 
Calcium can replace Mn(II) from manganese complexes in vivo due to their 
structure similarity, causing the release of Mn2+. The kinetic stability of Mn-DTPA 
cystamine copolymers and Mn-EDTA cystamine copolymers in the presence of Ca2+ was 
investigated in vitro by ultrafiltration as recently reported (17). Briefly, Mn-DTPA 
cystamine copolymers (0.71 mM-Mn) or Mn-EDTA cystamine copolymers (0.71 mM-
Mn) were incubated with CaCl2 (2 mM) in aqueous solution at physiological pH under 
room temperature for 1 hr.  The solution was then transferred to the sample reservoir of a 
centrifugal filter (Amicon Ultra®, 3000 Da molecular weight cut-off), and centrifuged at 
4000 rpm and 25 ºC for 20 min.	   	  The released Mn2+ was filtered through the membrane, 
and thus separated from the polymer bound Mn(II). The concentration of Mn(II) and 
Ca(II) in the pre-filtered solutions and the filtrates were determined by ICP-OES.  
Aqueous solutions of the polymers (0.71 mM-Mn) or CaCl2 (2 mM) were used as 
controls. The experiments were repeated in triplicate. The degree of transmetallation was 
calculated as the ratio percentage of the concentration of the released Mn2+ in filtrate over 






In Vitro Degradation  
The degradation of Mn-DTPA cystamine copolymers and Mn-EDTA cystamine 
copolymers was evaluated by in vitro incubation with cysteine.  The polydisulfide Mn(II) 
complexes (0.71 mM-Mn) were incubated with cysteine (15 µM) in PBS buffer at 
physiological pH.  Samples were collected before and at 15, 30, 60, 120, 360 min and 24 
hr during incubation. The molecular weight of the samples were determined using SEC 
(AKTA FPLC system with a Superose™ 6 column, GE Healthcare Life Sciences). The 
column was calibrated using water soluble poly[N-(2-hydroxylpropyl)methacrylamide] 
(HPMA) standards with a series of different molecular weight (Mn = 32, 47, 80 and 148 
kDa). 
 
Relaxivity Measurement   
The T1 relaxivity of the contrast agents was determined using a Siemens Trio 3T 
MRI scanner. T1 relaxation time of the aqueous solution of each contrast agent at 
different concentrations (0.2, 0.4, 0.6 and 0.8 mM) was measured using a saturation-
recovery pulse sequence at room temperature.  Data acquisition was completed at a fixed 
echo time (TE=11 ms) and different repetition times (TR=100, 200, 400, 800, 1600 and 
3200 ms).  The net magnetization (M) of each sample was measured using the software 
Osirix (http://www.osirix-viewer.com). T1 was derived from the nonlinear regression 
equation 
! 
M = M0(1" e
"TRT1 )  by fitting with the MATLAB software. Relaxivity was 
calculated as the slope of the plot of 1/T1 versus the concentration of Mn(II). Similarly, 
the T2 relaxivity was determined using the Bruker minispec relaxometer (1.5T, 60Hz).   
The Mn(II) content of each sample was confirmed by ICP-OES after the MR scanning. 
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Animal Tumor Model  
Female athymic nu/nu mice (4-6 weeks old) weighted 18-22 g were purchased 
from the National Cancer Institute (Frederick, MD).  The animals were cared following 
an approved protocol and the guidelines of the local Institutional Animal Care and Use 
Committee. The mice were subcutaneously implanted in both flanks with 2 × 106 MDA-
MB-231 cells in a mixture of 50 µL culture medium and 50 µL Matrigel.  The MRI study 
was performed when the tumor size reached 0.5-1.0 cm in diameter in 3~4 weeks.  
 
Contrast Enhanced MR Imaging  
The contrast enhancement of polydisulfide Mn(II) complexes was investigated in 
female nu/nu athymic mice with MDA-MB-231 breast cancer xenografts.  The mice were 
anaesthetized by i.p. injection of a mixture of ketamine (80 mg/kg) and xylazine (12 
mg/kg).  A wrist coil was used for image acquisition.  The MR images were acquired on 
a Siemens Trio 3T MR scanner with a 3D FLASH pulse sequence (TE = 2.74 ms, TR = 
7.73 ms, flip angle = 25°, slice thickness = 0.5 mm, 128×256×48 matrix size, 120 mm 
field of view, 0.39×0.39×0.5 mm3 spatial resolution, 3 averages) and a 2D spin-echo 
sequence (TE=8.9 ms, TR=400 ms, flip angle=90°, slice thickness = 2.00 mm, 128×256 
matrix size, 120 mm field of view, 0.25×0.25×2 mm3 spatial resolution, 3 averages).  
Three tumor bearing mice were used for each contrast agent. The contrast agents were 
administered to the anesthetized mice at a dose of 0.05 mmol-Mn/kg via tail vein 
injection. Images were acquired before administration and at 2, 5, 10, 15, 30, 60 minutes 
post injection. The anesthetized mice were kept warm using a warming pad during and 
between image acquisitions. Signal intensity of the regions of interest (ROIs) was 
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obtained using the Osirix software. Contrast to noise ratio (CNR) in the tumor was 
calculated using the equation CNR=(S-S0)/σn, where S (post injection) and S0 (thigh 
muscle) denote the signal within the ROIs, and σn are the standard deviation of random 
background noise. Statistical analysis was performed using a two-way ANOVA with 
Bonferroni’s, assuming statistical significance at p < 0.05. 
 
Results 
Synthesis of Polydisulfide Manganese(II) Complexes   
The synthesis of Mn-DTPA cystamine copolymers and Mn-EDTA cystamine 
copolymers is described in Figure 2.1. DTPA cystamine copolymers: 1H-NMR (300 
MHz, D2O, 25°C): 2.60-2.8 (t, 4H), 2.75-3.0 (s, 4H), 3.05-3.10 (t, 4H), 3.10-3.18 (s, 4H), 
3.18-3.30 (s, 4H), 3.35-3.45 (t, 4H), 3.55-3.66 (s, 2H); FR-IR: 2720-3800 cm-1 (νO-H ), 
1480-2000 cm-1 (νC=O), 1200-1480 cm-1 (δO-H, νC-O and νC-N).  The Mn(II) content in Mn-
DTPA cystamine copolymers was 9.84% (w/w). FR-IR: 2640-3600 cm-1 (νO-H ), 1480-
1760 cm-1 (νC=O), 1200-1480 cm-1 (δO-H, νC-O and νC-N).  EDTA cystamine copolymers: 
1H-NMR (300 MHz, D2O, 25°C): 2.65-2.8 (t, 4H), 3.0-3.2 (s, 4H), 3.35-3.50 (s, 8H), 
3.55-3.70 (s, 4H); FT-IR: 2800-3680 cm-1 (νO-H), 1440-1880 cm-1 (νC=O), 1200-1480 cm-1 
(δO-H, νC-O and νC-N). The Mn(II) content in Mn-EDTA cystamine copolymers was 
10.14% (w/w). FT-IR: 2640-3600 cm-1 (νO-H ), 1440-1720 cm-1 (νC=O), 1200-1480 cm-1 
(δO-H, νC-O and νC-N).The number average molecular weight (Mn) and weight average 
molecular weight (Mw) were 45.7 kD and 64.3 kD kDa for DTPA cystamine copolymers 
(polydispersity, PD = 1.4), and 156 and 255.3  kDa (PD = 1.6) for EDTA cystamine 
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average molecular weight were 30.50 and 37.35 kDa for Mn-DTPA cystamine 
copolymers (PD=1.2), and 61.80 and 126.37 kDa (PD = 2.0) for Mn-EDTA cystamine 
copolymers. 
  
Kinetic Stability   
Transmetallation, the replacement of Mn(II) ions in the chelates by endogenous 
metal ions, is considered as a main cause of in vivo kinetic instability for MR contrast 
agents based on paramagnetic metal chelates (2,3).  Ca(II) ions have the same charge and 
similar size as Mn(II) ions, and are abundantly present in human plasma.  As a result, 
plasma Ca(II) ions are considered as the main cause of in vivo transmetallation of Mn(II) 
complexes.  Ultrafiltration was effective to separate the released and bound Mn(II) 
species.  In the control studies, 88.5±4.6% free Ca2+ ions in CaCl2 aqueous solution was 
filtered through via ultrafiltration, while the bound Mn(II) ions of both polymeric 
chelates did not filter through the membrane.  Only 0.82± 1.1% Mn(II) was measured in 
the filtrate for Mn-DTPA cystamine copolymers, and 1.03±0.10 % for Mn-EDTA 
cystamine copolymers.  Figure 2.2 shows that in the presence of CaCl2, more Mn(II) 
(12.2±0.02%) was released from Mn-DTPA cystamine copolymers than that from Mn-
EDTA cystamine copolymers (3.36±0.08%).  The result indicates that Mn-EDTA 
cystamine copolymers were kinetically more stable than Mn-DTPA cystamine 












































































Figure 2.2. Transmetallation of  Mn-DTPA cystamine copolymer (MDCC), Mn-EDTA 
cystamine  Copolymer (MECC) with Ca2+. 
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In Vitro Degradation   
The degradation of polydisulfides Mn(II) chelates were verified by in vitro 
incubation studies. The Mn(II) chelates were incubated in 15 µM cysteine aqueous 
solution (the plasma concentration of free thiols) at physiological pH. Gradual decrease 
of molecular weight was observed for both Mn-DTPA cystamine copolymers and Mn-
EDTA cystamine copolymers, Figure 2.3. It appears that Mn-EDTA cystamine 
copolymers degraded more rapidly than Mn-DTPA cystamine copolymers.  The number 
average molecular weights (Mn) were 30.50, 29.34, 25.60, 23.57, 21.35, 18.64 and 13.50 
kDa for Mn-DTPA cystamine copolymers, and were 61.80, 56.45, 49.75, 45.36, 38.62, 
32.64 and 22.57 kDa for Mn-EDTA cystamine copolymers before and at 15, 30, 60, 120, 
360 and 24 hours post incubation with cysteine. Mn-DTPA cystamine copolymers were 
negatively charged and charge repulsion might inhibit the attack of the negatively 
charged cysteine at physiological pH to the disulfide bonds. In comparison, Mn-EDTA 
cystamine copolymers were neutral polymers and cysteine could readily react with the 
disulfide bonds. Consequently the neutral Mn-EDTA cystamine copolymers had a faster 
degradation rate than Mn-DTPA cystamine copolymers in the presence of cysteine, 
similar to previously reported polydisulfide Gd(III) complexes (9). 
 
Relaxivity 
Figure 2.4 shows the MR images of the aqueous solutions of Mn-DTPA 
cystamine copolymers, Mn-EDTA cystamine copolymers and MnCl2 at different Mn(II) 
concentrations acquired using the inversion-recovery sequence at 3T and the plot of 1/T1 







Figure 2.3. The molecular weight distribution before (blue line) and at 15, 30, 60, 120, 
360 and 24 hrs post incubation of the Mn-DTPA cystamine copolymer (A) and Mn-

















Figure 2.4. (A) MR imaging of aqueous solutions of MnCl2, Mn-DTPA cystamine 
copolymer (MDCC) and Mn-EDTA cystamine copolymer (MECC) at 
concentrations of 0.2, 0.4, 0.6 and 0.8 mM. (B) 1/T1 versus concentration plot of 






in the order of Mn-EDTA cystamine copolymers > Mn-DTPA cystamine copolymers > 
MnCl2. The longitudinal relaxivity (r1) was 2.4, 4.74 and 6.41 mM-1s-1 per Mn(II) for 
MnCl2, Mn-DTPA cystamine copolymers and Mn-EDTA cystamine copolymers, 
respectively. The r2 was 10.38 and 9.72 mM-1s-1 for Mn-DTPA cystamine copolymer and 
Mn-EDTA cystamine copolymer. 
 
In Vivo MR Imaging 
Figure 2.5 shows the T1-weighted coronal MR images of mice bearing MDA-MB-
231 human breast carcinoma xenografts before and after intravenous injection of MnCl2, 
Mn-DTPA cystamine copolymers and Mn-EDTA cystamine copolymers. The agents 
resulted in similar in vivo enhancement pattern, where significant enhancement was 
observed in the liver, blood pool, myocardium and bladder. The strong and prolonged 
liver enhancement was observed for all three agents. The polydisulfide Mn(II) complexes 
resulted in significant blood pool enhancement at 2 minutes post injection and the blood 
signal decreased afterwards. The MnCl2 control resulted in little blood pool enhancement, 
but significant enhancement in the myocardium during the experiment. Contrast 
enhancement in the urinary bladder increased for Mn-DTPA cystamine copolymers at 20 
minutes post injection and for Mn-EDTA cystamine copolymers at 5 minutes post 
injection. No signal enhancement was observed in the bladder for MnCl2 during the 
period of experiment. The results indicate that the polydisulfide Mn(II) complexes are 
degraded and excreted via renal filtration. EDTA cystamine copolymers excreted more 
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Figure 2.5. 3D coronal images before (0 min) and at 2, 5, 10, 30 and 60 minutes post 
injection of MnCl2, Mn-DTPA cystamine copolymers (MDCC), and Mn-EDTA 
cystamine copolymers (MECC) at a dose of 0.05 mmol-Mn(II)/kg.	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Figure 2.6 shows the axial T1-weighted 2D spin-echo MR images of the tumor 
before and at different time points after injection of the agents.  Slight enhancement was 
observed in the tumor with MnCl2 and Mn-DTPA cystamine copolymers.  Mn-EDTA 
cystamine copolymers resulted in more significant tumor enhancement than Mn-DTPA 
cystamine copolymers. Quantitative analysis of the contrast-to-noise ratio in the tumor 
periphery (Figure 2.7) showed that Mn-EDTA cystamine copolymers resulted in more 
significant tumor enhancement than Mn-DTPA cystamine copolymers and MnCl2 for at 
least 1 hour. 
 
Discussion 
In this study, we aim to develop Mn(II) based biodegradable macromolecular 
contrast agent as an alternative for Gd(III)-based contrast agents. Two types of 
Figure 2.6. 2D spin echo image of the tumor before and 2, 5, 10, 30 and 60 minute after 
intravenous injection of MnCl2, Mn-DTPA cystamine copolymers (MDCC) and Mn-




polydisulfide Mn(II) complexes, Mn-DTPA cystamine copolymer and Mn-
EDTAcystamine copolymer, were synthesized and evaluated. The polymeric ligands 
were synthesized based on reported protocol, followed by Mn(II) complexation.  After 
chelation, both polydisufide Mn(II)-DTPA and Mn(II)-EDTA showed decreased 
molecular weight and change in IR spectrum. The hydrodynamic volume of Mn(II) 
complexes appeared smaller because the polymer became nonionic after chelation. From 
the IR spectrum, red shift was observed with vibration peak of C=O (from 1480-2000 to 
1480-1760 for DTPA based Mn(II) chelates, and 1440-1880 to 1440-1720 for EDTA 
























Figure 2.7.  Contrast-to-Noise Ratio (CNR) of tumor periphery before and at 2, 
5, 10, 20, 30 and 60 minutes post tail vein injection of MnCl2 (circle), Mn-DTPA 
cystamine copolymers (square), Mn-EDTA cystamine copolymers (triangle) at a 
dose of 0.05 mmol-Mn/kg.	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and C-N (1200-1480) were observed for both Mn(II)-EDTA cystamine copolymer and 
Mn(II)-DTPA cystamine copolymer, indicating the contribution of the carbonyl oxygen, 
carboxylic oxygen and tertiary nitrogen for Mn(II) complexation. 
The polydisulfide Mn(II) complexes, Mn-DTPA cystamine copolymers and Mn-
EDTA cystamine copolymers, have shown some interesting features as compared to 
MnCl2 as MRI contrast agents.  The T1 relaxivity of the polydisulfide Mn(II) complexes 
was increased as compared to that of MnCl2 due to the increase of molecular size.  The 
macromolecular agents had large size and hydrodynamic volume, which significantly 
prolonged their rotational tumbling time, resulting in relaxivity increase. Although free 
Mn2+ might have more water molecules in the inner coordination sphere, the results in 
this study imply that the structure and size of the agents had a stronger impact on the 
relaxivity of the contrast agents than a large number of water molecules in the inner 
sphere (18). Recent studies have shown that the water exchange rate of manganese 
complexes was significantly faster than that of the gadolinium chelates, compensating the 
lower intrinsic paramagnetism of manganese (19).  Consequently, the r1 relaxivity of the 
polydisulfide Mn(II) complexes was comparable to that of polydisulfide gadolinium(III) 
complexes, Gd-DTPA cystamine copolymers (GDCC) at 3T (20).    
Mn-EDTA cystamine copolymers (6.41 mM-1s-1) had higher r1 relaxivity than 
Mn-DTPA cystamine copolymers (4.74 mM-1s-1). Although the former had higher 
molecular weight, the size of polydisulfides might not be the main cause of difference in 
relaxivity of the agents based on our previous observation on the polydisulfide Gd(III) 
complexes (15, 21). The high relaxivity of Mn-EDTA cystamine copolymers might be 
attributed to the low coordination number of EDTA bisamides in the copolymers, which 
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might result in more rapid water exchange of the chelates. The chelating groups are 6 and 
8 for the EDTA bisamide and DTPA bisamide in the polydisulfides, respectively. The 
coordination number of Mn(II) ions was up to 7 (22, 23), larger than the number of 
chelating groups in EDTA bisamide. One coordination site from Mn(II) was available for 
water complexation in Mn-EDTA cystamine copolymers, while there was no free 
coordination site from the Mn(II) complex in Mn-DTPA cystamine copolymers. The 
availability of inner sphere water binding could be the main reason for higher relaxivity 
of Mn-EDTA cystamine copolymers. Similar relaxivity difference between Mn-DTPA 
based chelates and Mn-EDTA based chelates were also observed in other Mn(II) based 
contrast agents (7, 24)  
In comparison with Gd(III) chelates (log KGd-DTPA=17.35, log KGd-DOTA=22.46), 
Mn(II) chelates (log KMn-EDTA=13.9, log KMn-DTPA=15.2) are less stable, generating more 
concerns on transmetallation and in vivo metal release. Ca2+ is structurally similar to 
Mn2+, and is viewed as the major cause of in vivo transmetallation for Mn(II) chelates 
(25, 26). Although the thermodynamic stability of Mn-DTPA chelates (log KMn-DTPA= 
13.5) are one to two magnitude higher than the Mn-EDTA chelates (log KMn-EDTA=14.31-
15.6), our kinetic stability study showed that Mn(II)-EDTA cystamine copolymers were 
more stable against Ca2+ transmetallation than Mn(II)-DTPA cystamine copolymers. 
After 1 hr incubation with Ca2+ under plasma concentration, less Mn2+ was released from 
Mn(II)-EDTA cystamine copolymers (3.36±0.08 %) than that from the Mn(II)-DTPA 
cystamine copolymers (12.2±0.02 %). The kinetic stability of metal chelates is generally 
affected by complicated factors. In our case, the higher kinetic lability of Mn(II)-DTPA 
based polydisulfide may be attributed to its more extended conformation in solution due 
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to the negative charges on the polymer, exposing higher extent of the chelates to the 
surrounded Zn2+ in solution (28). In addition, the negative charges on the subunits of 
MDCC can also facilitate the approach of Zn2+ to the chelates through ionic interactions. 
In comparison, MECC is a neutral polymer with a more compacted conformation, which 
can create additional steric hindrance against Zn2+ transmetallation in solution. The 
difference of kinetic stability against Zn(II) transmetallation between MDCC and MECC 
might not be as significant in vivo as that from in vitro experiments, since plasma Zn(II) 
is often presented in a protein-bound form instead of free ions in vivo.  
The degradability of MDCC and MECC were confirmed via in vitro incubation 
study using plasma thiol concentration of cysteine, an endogenous free thiol. During the 
incubation, no nitrogen protection was used to eliminate the impact of air on the 
oxidation of cysteine, which will gradually lose its reduction capacity through formation 
of the disulfide derivative of cystine during the incubation. As a result, more efficient 
degradation may be expected in vivo where plasma concentration of free thiols is in a 
more steady range.   
Polydisulfide Mn(II) complexes resulted in less contrast enhancement in the blood 
pool as compared to polydisulfide Gd(III) complexes reported in our previous studies 
(12).  Significant blood pool enhancement was observed in the first two minutes for the 
manganese based agents and then quickly disappeared, even for Mn-EDTA cystamine 
copolymers of high molecular weight.  In contrast, Gd-DTPA cystamine copolymers with 
similar r1 relaxivity and molecular weight resulted in more prolonged blood pool contrast 
enhancement (12). Polydisulfide Mn(II) complexes also resulted in strong and prolonged 
contrast enhancement in the liver, while Gd-DTPA cystamine copolymers had much less 
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contrast enhancement in the liver. Strong liver enhancement of polydisulfide Mn(II) 
complexes indicated liver affinity and high liver accumulation of the agents. The liver 
accumulation of Mn(II) based contrast agent may be attributed to favorable hepatic 
uptake of Mn(II). High and rapid liver accumulation of the agents could significantly 
reduce their concentration in the blood, consequently low blood pool enhancement.  
Mn-EDTA cystamine copolymers resulted in more prominent tumor enhancement 
than MnCl2 and Mn-DTPA cystamine copolymers in T1 weighted 2D spin-echo MR 
images.  However, the polydisulfide Mn(II) chelates generated less tumor enhancement 
than polydisulfide Gd(III) complexes (15, 21).  This could be attributed to the relatively 
low stability and high liver accumulation of the Mn(II) complexes. Between the tested 
Mn(II) based agents, Mn-EDTA cystamine copolymers had larger molecular weight, 
higher relaxivity and stability against transmetallation with Ca2+, and resulted in more 
significant tumor contrast enhancement. The polydisulfide Mn(II) complexes also 
facilitated the excretion of the agents via renal filtration, as evidenced by strong bladder 
enhancement at 60 minutes after the injection, while little MnCl2 was excreted via renal 
filtration.   
The design and development of Mn(II) based MRI contrast agents have recently 
attracted a significant amount of attention because of the better safety profiles of residual 
Mn(II) ions (34, 35). We have shown in this study that polydisulfide Mn(II) complexes 
had better relaxivity, pharmacokinetics, clearance and in vivo enhancement than MnCl2. 
In comparison to some recently reported dendritic agents and colloidal systems (7, 9, 10), 
our polydisufide based Mn(II) contrast agents, especially MECC, showed relatively 
higher relaxivity possibly due to the relatively large hydrodynamic volume of the 
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polydisulfides and the existence of inner sphere water binding site of the Mn-EDTA 
chelate. However, the main limitation of currently available Mn(II) complexes is their 
low complexation stability, including both thermodynamic and kinetic stabilities. Further 
studies are needed to design new Mn(II) chelates with high thermodynamic and kinetic 
stability in order to develop novel Mn(II) based contrast agents and to expand their 
application in MR imaging of other tissues and organs. The magnetic properties of Mn(II) 
based agents are also different from that of Gd(III)-based contrast agents. Mn(II) 
complexes often have much higher T2 relaxivity, which can significantly reduce the 
signal in T1-weighted imaging. This could be overcome by designing better imaging 
sequence to reduce T2 effect in T1-weighted MRI in the future studies. 
 
Conclusion 
In conclusion, two polydisulfide Mn(II) complexes were synthesized as 
gadolinium free biodegradable macromolecular MRI contrast agents. The 
macromolecular Mn(II) complexes readily degraded in the presence of endogenous free 
thiols.  Both polydisulfide Mn(II) complexes had similar r1 relaxivity as polydisulfide 
Gd(III) complexes, higher than that of MnCl2.  Mn-EDTA cystamine copolymers showed 
higher kinetic stability than Mn-DTPA cystamine copolymers against transmetallation 
with Ca2+ ions. Similar to other reported Mn(II) chelates, polydisulfide Mn(II) complexes 
resulted in prominent contrast enhancement in the liver and myocardium.  
Macromolecular Mn(II) complexes have a potential to be developed as effective contrast 
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SYNTHESIS AND EVALUATION OF A POLYDISULFIDE  
WITH GD-DOTA MONOAMIDE SIDE CHAINS AS  
A BIODEGRADABLE MACROMOLECULAR  
CONTRAST AGENT FOR MR  
BLOOD POOL IMAGING 
 
Introduction 
Magnetic resonance imaging (MRI) is a clinical diagnostic modality without 
ionization radiation and provides both morphological and functional information (1, 2).  
In comparison with other clinical imaging modalities, MRI is advantageous in visualizing 
soft tissues with high spatial resolution.  In order to provide more accurate diagnostic 
imaging, contrast agents are often used to enhance the image contrast between the tissue 
of interest and its surrounding tissues. Over the past 30 years, various paramagnetic 
compounds have been investigated as MRI contrast agents (3-6). Among these 
compounds, stable Gd(III) chelates are most commonly used in clinical practice (7). The 
small molecular Gd(III)-based clinical agents with short blood half-lives have relatively 
low relaxivities, rapidly extravasate from vasculature and excrete through renal 
glomerular filtration (8,9). These drawbacks limit their applications in clinical blood pool 
MRI, including both MR angiography and cancer imaging (10,11). 
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Two types of blood pool imaging agents, the small Gd(III) chelates that reversibly 
bind to plasma proteins such as MS-325 and macromolecular Gd(III) complexes, have 
been developed to address the limitations of clinical agents (12–16). Although MS-325 is 
effective for MR angiography, it is not as effective as polymeric Gd(III) chelates for 
evaluating tumor vascularity (11,17–19). Macromolecular Gd agents, such as polylysine 
Gd(III) chelate conjugates, polysaccharide Gd(III) chelate conjugates, Gadomer 17, 
PAMAM dendrimer Gd(III) chelate conjugates (20–23), are generally prepared by 
conjugating stable Gd(III) chelates to biocompatible polymers (24,25). These 
macromolecular agents have high relaxivities (in the range of 7~25 mM−1s−1 at 1.5T) 
(15,20–23), about 2–4 folds higher than their small molecular counterparts such as Gd-
DTPA and Gd-DOTA (generally in the range of 3~5 mM−1s−1 at 1.5T) (3,26) due to 
slower molecular rotational correlation time. They also exhibit prolonged blood 
circulation and limited extravasation (25,27). Preclinical studies have shown that these 
macromolecular agents are effective for MR angiography, cancer imaging and 
characterization of tumor vascularity (28,29). Although macromolecular Gd(III) 
complexes have demonstrated some advantageous features over small molecular Gd(III) 
chelates, including both protein binding and non-binding agents, in preclinical studies, 
the clinical application of macromolecular Gd(III) based contrast agents has been 
impeded by the safety concerns associated with their slow excretion, which can lead to 
significantly higher tissue deposition of Gd(III) complexes than the small molecular 
agents (8), and consequently increase the probability of toxic Gd(III) ion release, causing 




In order to alleviate the safety concerns of macromolecular contrast agents, we 
have recently developed extracellular degradable polydisulfides based polymeric MR 
contrast agents to accelerate the clearance of Gd chelates and minimize the tissue 
accumulation of Gd after the MRI examinations (29, 32, 33). These agents were prepared 
by copolymerization of DTPA anhydride with disulfide-contained monomers, followed 
by complexation with Gd(III). The disulfide bonds in the polymeric backbone was 
readily cleaved by in vivo plasma free thiols through disulfide-thiol exchange reaction.  
Pharmacokinetic studies revealed that the polydisulfide Gd chelates act as 
macromolecular contrast agents initially after administration, and are gradually reduced 
into excretive oligomeric and small Gd chelates in plasma, which are readily eliminated 
via renal filtration with a Gd(III) tissue retention comparable to clinical Gd(III) based 
MRI contrast agents. Preclinical studies showed that the polydisulfide Gd-DTPA 
complexes had better efficacy for contrast enhanced vascular and tumor imaging and 
characterization of tumor vascularity than small molecular Gd(III)-based contrast agents 
(34, 35). However, linear chelates, Gd-DTPA and its derivatives, exhibit relatively low 
kinetic stability, which may result in the release of free Gd(III) ions in vivo via 
transmetallation with endogenous metal ions (30, 31, 36, 37).  
Chelate structure plays an essential role in the overall stability of Gd complexes, 
including the thermodynamic stability and the kinetic inertness (8, 36-38). The current 
clinically available Gd-based contrast agents are prepared from the derivatives of two 
types of ligands, the linear ligands, diethylenetriaminepentaacetic acid (DTPA) amd its 
derivatives, and the macrocyclic ligand, 1,4,7,10-tetraazacyclododecome-1,4,7,10-
tetraacetic acid (DOTA) and its derivatives. The macrocyclic Gd(III) complexes exhibit 
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much higher kinetic stability than the linear Gd(III) chelates and no transmetallation in 
the presence of endogenous metal ions (39-41). The polydisulfides Gd-DTPA complexes 
had similar kinetic stability as the linear Gd(III) agent MultiHance®, higher than that of 
Omniscan®, but lower than that of the macrocyclic agent ProHance® (42). Previously, 
we investigated two biodegradable macromolecular contrast agents based on the more 
stable macrocyclic chelates, poly(L-glutamic acid)-cystamine-(Gd-DOTA monoamide) 
conjugate and the PAMAM-cystamine-(Gd-DOTA monoamide) conjugate (43, 44). Both 
systems showed good tumor diagnosis capacity as well as improved elimination in 
comparison to their non-degradable counterparts. However, limitations were also 
observed for these agents.  The poly(L-glutamic acid) conjugates eliminated much slower 
than the polydisulfide GDCC due to the steric hindrance of randomly coiled structure of 
the polymer backbone on the reduction of the disulfide spacer (43, 45). The PAMAM 
conjugate had efficient degradation, but dendrimer became highly toxicity after the 
disulfide cleavage (44). Therefore, we hypothesized that the combination of macrocyclic 
chelates Gd(III) and polydisulfides can produce safe and effective biodegradable 
macromolecular blood pool agents with a clinical potential.  
In this study, we have designed and synthesized a new generation of 
polydisulfides based on the macrocyclic Gd chelates to imrpove their kinetic stability. 
Herein, we report the synthesis of a polydisulfide with Gd-DOTA monoamide side chains, 
the copolymers of (N6-lysyl)lysine Gd-DOTA monoamide and 3-(2- 
carboxyethyldisulfanyl)propanoic acid (GODC), as a new biodegradable macromolecular 
MRI contrast agent. We characterized the kinetics stability of G(III) chelates in the agents 
and in vitro and in vivo degradation of the polymers. We evaluated the effectiveness of 
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Fmoc-lys(ivDDe)-OH was purchased from Chem-Impex International (Wood 
Dale, IL).  2-chlorotrityl chloride resin, 1-hydroxybenzotriazole (HOBT), 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate	   (PyBOP) were 
purchased from Nova Biochem (Darmstadt, Germany). 1,4,7,10-Tetraazacyclododecane-
1, 4,7-tris-tert-butyl acetate-10-acetic acid [DOTA-tris(t-Bu)] was purchased from TCI 
America (Portland, OR). N,N-Diisopropylethylamine (DIPEA), piperidine, hydrazine and 
trifluoroacetic acid (TFA) were purchased from Alfa Aesar (Ward Hill, MA). N,N-
Dimethylformamide anhydrous (DMF), dichloromethane (DCM), methanol, ethyl ether 
and phosphate buffer saline (PBS) were purchased from Fisher Scientific (Pittsburgh, 
PA). Fmoc-lys(Fmoc)-OH, the Kaiser test kit, ethylenediamine dihydrochloride, 1,2-
ethanedithiol (EDT), triisopropylsilane (TIS), Xylenol orange, 
dithiobis(succinimidylpropioniate) (DSP) and Gd(OAc)3 were purchased from Sigma-
Aldrich, Inc. (Louis, MO). All reagents were used without further purification unless 
otherwise stated. The synthetic product was verified and characterized using high 
performance liquid chromatography (HPLC, Agilent), the matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectra (Bruker Autoflex III), 
1H-NMR (300 MHz Varian Gemini NMR spectrometer) and Fourier transform infrared 
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(FT-IR, Varian Inc.). The MALDI-TOF mass spectrum was acquired on a Voyager DE-
STR spectrometer (PerSpeptive BioSystems) in linear mode with R-cyano-4-
hydroxycinnamic acid as a matrix. The polymer conjugates were purified by 
ultrafiltration with Millipore’s Amicon Ultra-15 centrifugal filter of 3 kDa molecular 
weight cut-offs against de-ionized water. The Gd(III) and Zn(II) content was measured 
by inductively coupled plasma-optical emission spectroscopy (ICP-OES Optima 
3100XL, Perkin-Elmer, Norwalk, CT). 
 
Synthesis of (N6-Lysyl)lysine-DOTA  
(N6-Lysyl)lysine-DOTA was synthesized following a solid phase peptide 
chemistry approach. Fmoc-lys(ivDDe)-OH (0.52 g, 0.91 mmol) was first loaded to the 2-
chlorotrityl chloride resin (1.15 g, 1.50 mmol, swelled in dichloromethane) with 800 µl 
DIPEA in 10 ml DMF and shaken for 2 hrs. The reaction media was then filtered out, 
followed by blocking the un-reacted active sites on the resin using 10 ml of methanol 
with 400 µl DIPEA (20 min x 2). The resin was washed with DCM and DMF to exclude 
the excess reactants. A Kaiser test was carried out with a small amount of resin samples, 
and showed negative result (yellow color), indicating no detection of primary amines. 
The resin was then reacted with 10 ml 20% of piperidine/DMF to remove the Fmoc 
group. DCM and DMF were used to wash out the remaining piperidine. After the 
reaction, Kaiser test of the resin showed positive result (blue color), indicating the 
removal of the Fmoc group. DOTA-tris(t-Bu) ester (1.04 g, 0.91 mmol) was then reacted 
to the resin with HOBT (0.37 g, 0.91 mmol), HBTU (1.03 g, 0.91 mmol) and 300 µl 
DIPEA in 10 ml DMF. The reaction media was shaken for 2 hrs, washed with DCM and 
 	  
103 
DMF. The next step was carried out when Kaiser test showed negative results, indicating 
complete reaction of the primary amine. The resin was then reacted with 10 ml 2% 
hydrazine/DMF to remove the ivDDe group. After removal of the ivDDe group (positive 
Kaiser test), Fmoc-lys (Fmoc)-OH (1.60 g, 0.91 mmol) was loaded to the resin with 
PyBOP (1.41 g, 0.91 mmol), HOBT (0.37 g, 0.91 mmol) and 500 µl DIPEA in 10 ml 
DMF. The reaction was carried out for 50 minutes. The Fmoc group was then removed 
using 10 ml 20% piperidine/DMF. After removal of the Fmoc, the resin was washed with 
DCM, dried. A mixture of trifluoroacetic acid (TFA), 1,2-ethanedithiol (EDT), water, 
TIS (95:2.5:2.5:2, 15 ml) was used to remove the tert-butyl groups and separate the final 
product from the resin. The reaction media was filtered out, and the raw product of (N6-
Lysyl)lysine-DOTA was precipitated in ethyl ether. The precipitate was recrystallized in 
DMSO and DIPEA (5:1). DIPEA also served as a base to remove TFA from the (N6-
lysyl)lysine DOTA monoamide. HPLC was used to verify the purity of the final product 
and showed good purity of the monomer after the recrystallization. The resulted DOTA 
monoamide was then characterized by 1H-NMR and MALDI-TOF mass spectrometry. 
The yield of the monomer was 62%. 1H-NMR (300 MHz, D2O, 25°C): 1.20-1.35 (m, 
4H), 1.40-1.50 (m, 2H), 1.55-1.85 (m, 6H), 2.85-2.95 (t, 2H), 2.98-3.50 (m, 19H), 3.60-
4.05 (m, 8H), 4.15-4.25 (t, 1H). MALDI-TOF MS: 661.02 (M+H+), 683.19 (M+Na+) 







Synthesis of (N6-Lysyl)lysine-DOTA monoamide and 
3-(2-carboxyethyldisulfanyl)-propionic Acid 
Copolymers (GODC)   
The polymerization was performed by slowly adding the DMF solution of 
dithiobis(succinimidylpropionate) (DSP) (0.2 g, 0.45 mmol) portion by portion to the 
concentrated aqueous solution of (N6-Lysyl)lysine-DOTA monoamide (0.4 g, 0. 45 mmol 
in 0.5 ml DI water)  while stirring. The reaction was stirred at room temperature for 4 
hours after adding the DSP solution. The product was purified through ultrafiltration 
using a filter with a molecular weight cut-off of 3,000 Da to remove low molecular 
weight oligomers, and then lyophilized to give the colorless polymeric ligand.  The yield 
of the purified product was 10%. The apparent number- and weight-average molecular 
weights of the copolymers were determined using size exclusion chromatography on an 
AKTA FPLC system with a Superose™ 12 column (GE Healthcare Life Sciences). The 
column was calibrated using water soluble poly[N-(2-hydroxylpropyl)methacrylamide] 
(HPMA) standards with number average molecular weight of 14, 23, 32 and 47 kDa. 
Polymers with molecular weight lower than 10 kD cannot be separated effectively using 
this column. The polymeric ligand was characterized by 1H-NMR and FT-IR. 1H-NMR 
(300 MHz, D2O, 25°C): 1.05-1.20 (m, 4nH), 1.20-1.40 (s, 4nH), 1.40-1.68 (m, 4nH), 
2.25-2.65 (m, 8nH), 2.70-3.14 (m, 16nH), 3.15-3.45 (s, 8nH), 3.50-3.75 (d, 4nH), 3.76-
4.20 (s, 2nH). FT-IR: 2800-3680 cm-1 (νO-H), 1440-1800 cm-1 (νC=O), 1100-1240 cm-1 (δO-





Complexation with Gd(III)   
The polymeric ligand was complexed with two folds excess of Gd(OAc)3 at pH 6 
for 48 hrs at room temperature. The resulting solution was purified via dialysis against 
water using a membrane with molecular weight cut-off of 8,000 Da, and lyophilized to 
give a final white product, (N6-Lysyl)lysine-Gd-DOTA monoamide 3-(2-carboxyethyl-
disulfanyl)-propionic acid copolymer (GODC). Size exclusion chromatography was used 
to determine the apparent molecular weights of the complexed polymer. Xylenol orange 
was used to detect the presence of free Gd(III) ions.  No color change was observed with 
Xylenol orange in the polymer solution after dialysis, indicating complete removal of the 
excess of Gd(OAc)3. The Gd(III) content of the polymer was determined using inductive 
coupled atomic emission spectrometry (ICP-OES, PerkinElmers®). The size of GODC in 
aqueous solution was determined using dynamic light scattering (DLS). The experiment 
was performed using a Brookhaven BI-200SM goniometer and BI-9000AT digital 
correlator equipped with a He-Ne laser (λ=633 nm) at room temperature. GODC in de-
ionized water (1.33 mg/ml) was filtered through a 0.22 μm filter and measured at a 
scattering angle of 90. A Nanosphere™ polystyrene size standard (diameter=102 nm ± 3 
nm) (Thermo Scientific, Waltham, MA) was analyzed in line to confirm accuracy. All 
measurements were performed 3-5 times.  
 
Relaxivity Measurement   
The T1 relaxivity of GODC was determined using a Bruker Minispec® 
Relaxometer (1.5T, 60 Hz) at 37°C.  Different concentrations of GODC (0.2, 0.4, 0.6 and 
0.8 mM of Gd) were prepared, and their T1 values were obtained using an inversion-
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recovery pulse sequence from the relaxometer. The longitudinal relaxivity (r1) was 
calculated as the slope of the plot of 1/T1 versus the concentration of Gd(III). Similarly, 
the T2 relaxivity was determined using a Carr-Purcell-Meiboom-Gill (CPMG) spin echo 
method. The Gd(III) content of each sample was confirmed by ICP-OES after the MR 
measurement. 
 
Degradation of the Polydisulfide  
In vitro degradation study of GODC polymer was carried out via incubation of 
GODC (0. 42 mM-Gd) with cysteine at plasma thiol concentration (15 µM) (46, 47) to 
mimic the in vivo conditions. The polydisulfide with 0.42 mM of Gd(III) were incubated 
with 15 µM L-cysteine in PBS buffer at pH 7.4 and 37°C for 24 hours. The change of 
apparent molecular weight of GODC during the incubation was determined using size 
exclusion chromatography (Superose® 12 column, AKTA® FPLC). The column was 
calibrated using water soluble poly[N-(2-hydroxylpropyl)methacrylamide] (HPMA) 
standards with a series of different molecular weight (Mn = 14, 23, 32 and 47 kDa). 
The degradation mechanism of the polydisulfide was also investigated both in 
vitro and in vivo. For in vitro experiment, GODC was incubated with an excess of L-
cysteine (1.5 mM) in PBS solution at 37°C for 60 minutes.  The reaction mixture was 
analyzed by MALDI-TOF mass spectrometry.  For in vivo experiment, GODC was 
administered to mice at a dose of 0.1 mmol-Gd/kg via a tail vein, and urine samples were 
collected 30 minutes after the injection and analyzed by MALDI-TOF mass 
spectrometry. 
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Kinetic Inertness  
The kinetic inertness of polydisulfide Gd-DOTA against transmetallation was 
evaluated in vitro in comparison with our previously reported Gd-DTPA cystamine 
copolymers (GDCC) (48). GODC (0.42 mM-Gd) or GDCC (0.42 mM-Gd) was incubated 
with ZnCl2 at the plasma Zn2+ concentration (50 µM) in PBS buffer at pH=7.4 and 37°C 
for 2 hrs. Samples were collected before and at 30, 60 and 120 minutes of incubation. 
The polymer bound Gd(III) and released Gd(III) ions were separated using a PD-10 
column (GE Health Science). The concentration of polymer bound Gd(III) was measured 
by ICP-OES (Perkin-Elmers). The kinetic stability was determined as the percentage of 
bound Gd(III) in polymers post-incubation to that before-incubation. GODC and GDCC 
incubated with Zn2+ free PBS buffer were used as negative controls.  
 
Mouse Tumor Model  
Female BALB/c mice weighing 18-22 g were purchased from Charles River 
(Wilmington, MA, USA). The animals were cared following an approved protocol and 
the guidelines of the Animal Resource Center of Case Western Reserve University. 
Mouse breast cancer 4T1 cells (5 x 104 cells suspended in 50 µl Matrigel) were injected 
into the inguinal mammary fat pads of mice.  The MRI study was performed when tumor 
size reached 0.5-1.0 cm in diameter in 2 weeks.  
 
In Vivo MRI Study   
The contrast enhancement of GODC was preliminarily evaluated in mice using 
the clinical agent Magnevist® as a control. The tumor bearing mice were anaesthetized 
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with 2.5% ~ 3.5% of isoflurane in oxygen initially, and maintained at 1.5%-2.5% during 
the experiment.  The temperature, respiration and electrocardiograms (ECGs) of the mice 
were monitored during image acquisitions.  The animals were kept warm at 34°C using 
an air conditioning system controlled through a temperature module. The contrast agent 
was intravenously administered to anesthetized mouse via tail vein at a dose of 0.1 mmol-
Gd/kg. MR images were acquired before administration and at different time points post 
injection for up to 30 minutes on a Siemens 1.5T clinical scanner with a 3D FLASH 
pulse sequence (211 FOV, 1.1 mm slice thickness, 14.0 ms TR, 3.09 ms TE, 25° flip 
angle, 2 averages, 64×256 matrix size, 32 slices per slab) and a 2D spin-echo sequence 
(19.1 ms TE, 465 ms TR, 25° flip angle, 0.8 mm slice thickness, 100×256 matrix size, 
211 mm FOV, 2 averages).  Three tumor-bearing mice were used for each contrast agent.  
Signal intensity of the regions of interest (ROI) was measured using the Osirix software. 
Signal increase of the tumor periphery was calculated using the ratio of the signal post-
contrast to that of pre-contrast within the ROI at different time points post injection. 
Statistical analysis was performed using a two-way ANOVA with Bonferroni’s, 
assuming statistical significance at p < 0.05. 
 
Results 
Synthesis of (N6-Lysyl)lysine-DOTA-Gd Monoamide 
 and 3-(2-carboxy-ethyldisulfanyl)propanoic Acid  
Copolymers (GODC) 
The monomer containing Gd-DOTA, (N6-Lysyl)lysine-DOTA-Gd, was first 







Figure 3.1. Synthetic scheme of (N6-lysyl)lysine DOTA monoamide. 	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macromolecular MRI contrast agent, (N6-Lysyl)lysine Gd-DOTA monoamide and 3-(2-
carboxyethyldisulfanyl)propanoic acid copolymers (GODC), was synthesized by 
condensation polymerization of the Gd-DOTA monoamide and dithiobis(succinimidyl-
propionate) (Figure 3.2). The polymeric ligand, (N6-Lysyl)lysine DOTA monoamide and 
3-(2-carboxyethyldisulfanyl)propanoic acid copolymers, was characterized using 1H-
NMR and FT-IR.  The apparent number average and weight average molecular weights 
of the polymeric ligand were 20.7 and 25.8 kDa. After complexation, the final product 
GODC were purified against deioniazed water using dialysis membrane with higher 
molecular weight cutoff to further narrow down the polydispersity. The resulting number 
average and weight average molecular weight of GODC were 24.2 and 26.4 kDa, 
respectively.  The Gd(III) content in the agent was 15.08% (w/w) as determined by ICP-
OES. The calculated Gd content was 15.63% (w/w). The efficiency of complexation was 
96.5%. The DLS measurement showed the hydrodynamic effective diameter of GODC to 
be around 5-7 nm. The r1 and r2 relaxivities of GODC were 8.25 mM-1s-1  (Figure 3.3a) 
and 10.08 mM-1s-1 (Figure 3.3b) at 1.5 T. The T1 relaxivity (r1) of GODC increased 
approximatly 2 folds compared to the r1 of Gd(DO3A-HP) (ProHance®, 4.1 mM-1s-1 at 
1.5T, 20°C) (26).  
 
Degradability of GODC   
The polydisulfide structure of GODC was designed so that the polymers could be 
readily degraded and excreted via renal filtration in vivo through the disulfide-thiol 
exchange reaction (32).  The degradability of GODC was demonstrated via the 













Figure 3.2. Synthetic scheme of (N6-lysyl)lysine-(Gd-DOTA) monoamide 3-












Figure 3.3.  The relaxation rate 1/T1 (a) and 1/T2 (b) versus concentration plot of 





shows that the number average molecular weight of GODC decreased from 24.2 kDa 
before incubation to 23 kDa, 22.1 kDa, 19.7 kDa, 18.6 and 13.1 kDa at 30, 60, 120, 240 
min, and 24 hrs in the incubation. In terms of degree of polymerization, the average 
chelates per chain reduced from 25 to 12 after 24 hrs of in vitro incubation.  
The degradation mechanism was demonstrated both in vitro and in vivo. In vitro 
experiments revealed that the polydisulfides can be reduced to their smallest repeating 
units via disulfide-thiol exchange reaction when sufficient amount of free thiols was 
provided (Figure 3.5). Figure 3.6a showed the MALDI-TOF mass spectrum of the 60-
minutes-incubation mixture of GODC and excess of L-cysteine. The peaks of in vitro 
degradation products were compound I (m/z=978.3, M+; m/z=1000.8, M+Na+; 
m/z=1022.4, M+2Na+), the smallest building block of the polymer. In vivo analysis of 
metabolites in urine samples also illustrated similar route of degradation. Similar 
degradation products [m/z=1000 (I+Na+)] and the other degradation product of cysteine, 
compound II [m/z=1212 (M+H+)], were also identifed by MALDI-TOF mass  
Figure 3.4.  The apparent molecular weight distribution before (0 min) and in the 
incubation of GODC against cysteine (15 µM) at plasma concentration for 30, 60, 120, 













Figure 3.6. The MALDI-TOF mass spectrum of degradation products (a) 
collected 60 minutes post incubation of GODC with an excess of L-cysteine (1.5 













Figure 3.6. Continued. 	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spectrometry in urine samples collected 8 hours after intravenous injection of GODC 
(Figure 3.6b). The major metabolites in the urine samples had the mass of 1000.8 
(I+Na+), 1134.4 (compound I-homocysteine+Na+), 1212.5 (II+H+) and 1293.7 (unkown). 
 
Kinetic Inertness of GODC   
The new macrocyclic Gd chelate based polydisulfide, GODC, demonstrated much 
higher kinetic inertness against transmetallation than that of the linear Gd chelates based 
polydisulfides, GDCC.  Figure 3.7 reveals gradual loss of polymer bound Gd with GDCC 





Figure 3.7. The Gd(III) content in GDCC (square) and GODC (circle) before and 
in the incubation in PBS buffer with ZnCl2 (50 µM, filled) and without ZnCl2 




vitro incubation with Zn2+, whereas neglegible loss of Gd was observed with GODC. The 
Gd content remained similar over time for the control samples of GDCC and GODC, as 
well as the incubated samples of GODC, indicating good kinetic stability of the 
macrocyclic Gd based polydisulfides. 
 
In Vivo MR Imaging   
Figure 3.8 shows the T1-weighted 3D maximum intensity projection MR images 
of mice bearing orthotopic 4T1 mouse malignant tumor before and after intravenous 
injection of GODC and Magnevist®.  Significant and prolonged blood pool contrast 
enhancement was observed with GODC in comparison with Magnevist®, indicating the 
relatively prolonged blood circulation of GODC. The blood pool enhancement was 
gradually descreased, but still visible at 30 minutes post injection. Contrast enhancement 
inside the urinary bladder was observed at 3 minutes post injection of Magnevist®, and at 
10 minutes post injection of GODC, indicating relatively fast excretion of GODC. Figure 
3.9a shows the axial T1-weighted 2D spin-echo MR images and signal intensity ratio of 
the tumor before and at different time points after injection of the agents. GODC resulted 
in more significant enhancement in the tumor periphery of mice than that of Magnevist®.  
Quantitative analysis of the signal intensity in the tumor periphery showed that GODC 
produced stronger signal enhancement in the tumor than Magnevist® for at least 30 





Figure 3.8. Three-dimensional maximum intensity projection images (coronal 
view) of mice bearing 4T1 breast tumor xenografts before and at 1, 3, 5, 10, 15 
and 30 minutes post injection of Magnevist® and GODC at a dose of 0.1 mmol-
Gd/kg. The major organs were pointed out as H (heart), L (liver), K (kidney), B 














Figure 3.9. a) Axial 2D spin echo images of mice bearing 4T1 breast tumor 
xenografts before and at 1, 3, 5, 10, 15 and 30 minutes post injection of 
Magnevist® (A) and GODC (B) at a dose of 0.1 mmol-Gd/kg. b) Signal intensity 
ratio of tumor periphery of mice bearing malignant breast cancer before and at 








A polydisulfide with macrocyclic Gd(III) chelate side chains, 2,2',2''-(10-(2-((1-
carboxy-5-(2,6-diaminohexanamido)pentyl)amino)-2-oxoethyl) Gd-DOTA monoamide 
and 3-(2-carboxyethyldisulfanyl)propanoic acid copolymers (GODC), was synthesized 
asa new generation of disulfide based biodegradable macromolecular MRI contrast agent 
with improved kinetic inertness against the previously reported DTPA based agents (32, 
35). The monomer (N6-Lysyl)lysine DOTA monoamide had an unsymmetrical structure 
as shown in Figure 3.1. In consequence, the condensation polymerization of the 
monomers could result in polymer chains with random arrangement of the (N6-
Lysyl)lysine Gd-DOTA monoamide. The final product of GODC could have three 
possible arrangements of the lysine based Gd-DOTA monoamide in the polymer chains: 
two α-amines of separate Gd-DOTA monoamide molecules connected to the same DSP 
molecule, two ε-amines connected to the same DSP, and one α-amine and one ε-amine 
connected to DSP.  The polymerization might also result in cyclized products. High 
concentrations of monomers (0.8 g/ml of DI water)  were used in the polymerization 
reaction to minimize the cyclization. Differences in monomer arrangement in the polymer 
chains should not affect the degradability and magnetic properties of GODC as a 
biodegradable macromolecular MRI contrast agent. Despite molecular weight, the actual 
size of GODC in solution was measured using dynamic light scattering. The 
hydrodynamic diameter of GODC in solution was around 5-7 nm, right above the renal 
filtration threshold without degradation. To demonstrate the indispensability of 
degradation, we have also compared the pharmacokinetics and long-term tissue retention 
of the degradable polydisulfides Gd-DTPA agents with their non-degradable counterparts 
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of similar molecular weight (Mn= 25 kDa, PD=1.4) in our previous study (49). The result 
showed significantly longer blood circulation and higher tissue retention of the non-
degradable agents, indicating a need of degradation for polymers with similar structure. 
GODC was hypothesized to be degraded by extracellular free thiols through the 
thiol-disulfide exchange reaction. In vitro preliminary study was performed via 
incubation of GODC with L-cysteine at plasma concentration to demonstrate the 
mechanism and process of degradation. L-cysteine was chosen because it is the most 
abundant species among various types of small-molecular plasma thiols, including 
glutathione, homocysteine and cysteinylglycine (46). The in vitro incubation study 
showed that GODC was gradually reduced into oliogomers in the presence of cysteine at 
plasma-thiol concentration (15 µM), and can be completely degraded into the smallest 
repeating units when given sufficient cysteine. Besides cysteine, serum albumin is 
another abundant source of plasma thiols. Although it is of high concentration in plasma, 
it has been found that serum albumin plays little part in the reduction process of the 
polydisulfides in vivo (48). The high steric hindrance of both the protein and polymers 
greatly constrained the exchange reaction between the thiol in serum albumin and the 
polydisulfides. In addition to the in vitro incubation study, the mechanism of in vivo 
degradation was also validated through mass spectrometric analysis of the urine sample 
after injection of GODC. Similar peaks, including the smallest building block of GODC 
and the cysteine reduced products, were identified in the mass spectrum of both complete 
in vitro degradation products and the urine metabolites, indicating similar route of 
degradation in vitro and in vivo. Moreover, the discovery of reduction products other 
than cysteine metabolites in the urine samples (e.g the homocysteine metabolites with 
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peaks at m/z=1134.4) further verified the degradation mechanism, and more importantly, 
provided a more complicated insight of the in vivo metabolism pathway.  
 The in vitro degradation rate of GODC appeared slower than that of our previous 
reported GDCC (50), which is mainly a result of polymer charge. In physiological pH, 
GODC was negatively charged due to the extra carboxylic groups on the side chain, 
whereas GDCC was a neutral polymer. Since cysteine was also negatively charged at 
physiological pH, the negative charges around the disulfide bonds in GODC inhibited the 
approach of the cysteine due to charge repulsion, resulting in slower degradation. Similar 
results were also observed with other negatively charged polydisulfides, e.g. Gd-DTPA 
cystine copolymers (50). The in vitro degradation rate of GODC appeared significantly 
slower in comparison to in vivo degradation, which was indirectly demonstrated with 
rapid bladder enhancement in the mouse MR study. This difference of degradation rate 
can be attributed to various reasons since the in vivo degradation pathway is much more 
complicated. One explanation might be the difference of thiol concentration, which was 
fixed during the in vitro study, but was constantly replenished by the liver in vivo. In 
addition, if taking account of the impact of air on cysteine oxidation during the in vitro 
incubation study, the cysteine concentration might be gradually decreased through 
formation of cystine, leading to slower degradation than that from in vivo condition.  
Given the complicated nature of the in vivo metabolism environment for GODC, the in 
vitro degradation study was only a preliminary proof-of-concept study that can hardly be 
considered a good simulation of in vivo degradation. Further studies of pharmacokinetics, 
biodistribution, metabolite analysis and etc will be carried out to look deeper into the 
route of in vivo fate of the new polydisulfides Gd-DOTA. 
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Similar to our previously reported polydisulfides Gd-DTPA, the newly developed 
Gd- GODC exhibited significantly higher relaxivities than Gd-DOTA and Gd(DO3A-
HP) (ProHance®) (29, 35).  The T1 relaxivity of GODC was approximately two times 
higher than that of Gd-DOTA and Gd(DO3A-HP) at 1.5 T.  The significant increase of T1 
relaxivity of GODC might be attributed to its relatively large molecular size and 
hydrodynamic volume. However, the relaxivity of GODC was lower in comparison to 
some dendrimer based Gd-DOTA contrast agents with similar molecular weight, such as 
the Gadomer 17 and PAMAM dendrimetic Gd conjugates (15, 22, 23). The relatively 
flexible hydrophilic backbone of the linear GODC polymer chains might partly 
compromise the slower-rotational-tumbling effect of macromolecules, resulting in limited 
increase of relaxivity. In comparison, the dendrimer based Gd chelates had more rigid 
structures, and thus was less restrained on the relaxivity enhancement.  
As expected, the macrocyclic-chelate-polydisulfide GODC showed higher kinetic 
inertness than GDCC, the linear-chelate-polydisulfides. Since endogenous Zn(II) were 
the major metal species causing in vivo transmetallation of Gd(III)-based contrast agents, 
the preliminary stability study was carried out through in vitro incubation of the 
polydisulfides with Zn2+ to assess and compare the stability of GODC and GDCC.  Little 
release of free Gd(III) ions from GODC were observed in the presence of Zn2+, a 
consistent result as reported with other macrocyclic Gd(III) chelates (8, 31, 42). To the 
contrary, GDCC experienced gradual loss of Gd(III) over time during the incubation, 
showing lower kinetic inertness. High kinetic inertness of the new Gd(III)-based MRI 
contrast agent was critical to allow complete excretion of the agent from the body and 
minimize the potential toxic side effects associated with prolonged retention of Gd(III)-
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based agents.  
GODC was effective for contrast enhanced blood pool imaging, generating strong 
contrast enhancement in the heart, vasculature and the tumor periphery.  In comparison to 
GDCC with similar molecular weight (34, 35), GODC appeared to produce longer blood 
pool enhancement, possibly due to its relatively slow degradation. Although 
characterized with slower degradation, the MR study revealed that GODC could still be 
readily excreted via renal filtration after in vivo degradation. Strong bladder enhancement 
was observed as early as 10 minutes post injection, indicating the excretion of degraded 
Gd(III) chelates. In comparison, the clinical agent Magnevist® resulted in shorter and 
weaker enhancement in the blood pool. The prolonged blood pool enhancement of 
GODC is mainly a result of its large hydrodynamic volume, which limited vascular 
extravasation, extented blood circulation and concentrated blood pool signals. In 
addition, the increased of relaxivity also contributed in the notable enhancement of blood 
pool signals during the MR examination. Stronger enhancement was generated in the 
tumor periphery using GODC in comparison with Magnetive®. However, little signal 
difference was observed in the tumor core between GODC and Magnevist®, which can 
be attributed to the high pressure in the necrotic tumor core that hindered the penetration 
of both agents. Overall, the new macrocyclic chelate based biodegradable 
macromolecular MR contrast agent GODC is more effective for contrast enhanced blood 







A new polydisulfide Gd-DOTA complex, GODC, was synthesized and evaluated 
as a biodegradable macromolecular MRI contrast agent (51). GODC demonstrated high 
kinetic stability against transmetallation with endogenous ions. It was readily reduced by 
endogenous thiols into smaller Gd(III) chelates or oligomers that could be easily excreted 
via renal filtration.  GODC is a safe and effective biodegradable macromolecular MRI 





1. Barrett T, Brechbiel M, Bernardo M, Choyke PL. MRI of tumor angiogenesis. J 
Magn Reson Imaging. 2007;26(2):235-249. 
 
2. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status 
and future directions. J Magn Reson Imaging. 2002;16(4):407-422. 
 
3. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents for 
NMR imaging: theory and design. Chem Rev. 1987;87(5):901-927. 
 
4. Koretsky AP, Silva AC. Manganese-enhanced magnetic resonance imaging 
(MEMRI). NMR Biomed. 2004;17(8):527-531. 
 
5. Hermann P, Kotek J, Kubicek V, Lukes I. Gadolinium(III) complexes as MRI 
contrast agents: ligand design and properties of the complexes. Dalton Trans. 
2008(23):3027-3047. 
 
6. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI 
contrast agents: structure, dynamics, and applications. Chem Rev. 
1999;99(9):2293-2352. 
 
7. Aime S, Cabella C, Colombatto S, Geninatti Crich S, Gianolio E, Maggioni F. 
Insights into the use of paramagnetic Gd(III) complexes in MR-molecular 
imaging investigations. J Magn Reson Imaging. 2002;16(4):394-406. 
 
8. Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, 
including gadolinium deposition. J Magn Reson Imaging. 2009;30(6):1259-1267. 
 
9. Bellin MF, Vasile M, Morel-Precetti S. Currently used non-specific extracellular 
MR contrast media. Eur Radiol. 2003;13(12):2688-2698. 
 
10. Schalla S, Higgins CB, Saeed M. Contrast agents for cardiovascular magnetic 
resonance imaging. Current status and future directions. Drugs R D. 
2002;3(5):285-302. 
 
11. Turetschek K, Floyd E, Helbich T, Roberts TP, Shames DM, Wendland MF, 
Carter WO, Brasch RC. MRI assessment of microvascular characteristics in 
experimental breast tumors using a new blood pool contrast agent (MS-325) with 
correlations to histopathology. J Magn Reson Imaging. 2001;14(3):237-242. 
 
12. Brasch RC. Rationale and applications for macromolecular Gd-based contrast 
agents. Magn Reson Med. 1991;22(2):282-287. 
 
13. Goyen M, Shamsi K, Schoenberg SO. Vasovist-enhanced MR angiography. Eur 
Radiol. 2006;16 Suppl 2:B9-14. 
 	  
128 
14. Brasch R, Turetschek K. MRI characterization of tumors and grading 
angiogenesis using macromolecular contrast media: status report. Eur J Radiol. 
2000;34(3):148-155. 
 
15. Bumb A, Brechbiel MW, Choyke P. Macromolecular and dendrimer-based 
magnetic resonance contrast agents. Acta Radiol. 2010;51(7):751-767. 
 
16. Lauffer RB, Parmelee DJ, Ouellet HS, Dolan RP, Sajiki H, Scott DM, Bernard PJ, 
Buchanan EM, Ong KY, Tyeklar Z, Midelfort KS, McMurry TJ, Walovitch RC. 
MS-325: a small-molecule vascular imaging agent for magnetic resonance 
imaging. Acad Radiol. 1996;3 Suppl 2:S356-358. 
 
17. Barrett T, Kobayashi H, Brechbiel M, Choyke PL. Macromolecular MRI contrast 
agents for imaging tumor angiogenesis. Eur J Radiol. 2006;60(3):353-366. 
 
18. Perreault P, Edelman MA, Baum RA, Yucel EK, Weisskoff RM, Shamsi K, 
Mohler ER, 3rd. MR angiography with gadofosveset trisodium for peripheral 
vascular disease: phase II trial. Radiology. 2003;229(3):811-820. 
 
19. Shamsi K, Yucel EK, Chamberlin P. A summary of safety of gadofosveset (MS-
325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data. 
Invest Radiol. 2006;41(11):822-830. 
 
20. Schuhmann-Giampieri G, Schmitt-Willich H, Frenzel T, Press WR, Weinmann 
HJ. In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular 
contrast agent for magnetic resonance imaging. Invest Radiol. 1991;26(11):969-
974. 
 
21. Helbich TH, Gossman A, Mareski PA, Raduchel B, Roberts TP, Shames DM, 
Muhler M, Turetschek K, Brasch RC. A new polysaccharide macromolecular 
contrast agent for MR imaging: biodistribution and imaging characteristics. J 
Magn Reson Imaging. 2000;11(6):694-701. 
 
22. Bryant LH, Jr., Brechbiel MW, Wu C, Bulte JW, Herynek V, Frank JA. Synthesis 
and relaxometry of high-generation (G = 5, 7, 9, and 10) PAMAM dendrimer-
DOTA-gadolinium chelates. J Magn Reson Imaging. 1999;9(2):348-352. 
 
23. Misselwitz B, Schmitt-Willich H, Ebert W, Frenzel T, Weinmann HJ. 
Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast 
agent. MAGMA. 2001;12(2-3):128-134. 
 
24. Ladd DL, Hollister R, Peng X, Wei D, Wu G, Delecki D, Snow RA, Toner JL, 
Kellar K, Eck J, Desai VC, Raymond G, Kinter LB, Desser TS, Rubin DL. 
Polymeric gadolinium chelate magnetic resonance imaging contrast agents: 




25. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI 
contrast agents. Chem Soc Rev. 2006;35(6):512-523. 
 
26. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of 
magnetic properties of MRI contrast media solutions at different magnetic field 
strengths. Invest Radiol. 2005;40(11):715-724. 
 
27. Aime S, Castelli DD, Crich SG, Gianolio E, Terreno E. Pushing the sensitivity 
envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents 
for molecular imaging applications. Acc Chem Res. 2009;42(7):822-831. 
 
28. Brasch R, Pham C, Shames D, Roberts T, van Dijke K, van Bruggen N, Mann J, 
Ostrowitzki S, Melnyk O. Assessing tumor angiogenesis using macromolecular 
MR imaging contrast media. J Magn Reson Imaging. 1997;7(1):68-74. 
 
29. Lu ZR, Ye F, Vaidya A. Polymer platforms for drug delivery and biomedical 
imaging. J Control Release. 2007;122(3):269-277. 
 
30. Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, 
Walter J, Weinmann HJ, Pietsch H. Preclinical investigation to compare different 
gadolinium-based contrast agents regarding their propensity to release gadolinium 
in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 
2008;18(10):2164-2173. 
 
31. Thomsen HS, Morcos SK. Nephrogenic systemic fibrosis and nonionic linear 
chelates. AJR Am J Roentgenol. 2007;188(6):W580; author reply W581. 
 
32. Lu ZR, Mohs AM, Zong Y, Feng Y. Polydisulfide Gd(III) chelates as 
biodegradable macromolecular magnetic resonance imaging contrast agents. Int J 
Nanomedicine. 2006;1(1):31-40. 
 
33. Zong Y, Wang X, Goodrich KC, Mohs AM, Parker DL, Lu ZR. Contrast-
enhanced MRI with new biodegradable macromolecular Gd(III) complexes in 
tumor-bearing mice. Magn Reson Med. 2005;53(4):835-842. 
 
34. Zong Y, Guo J, Ke T, Mohs AM, Parker DL, Lu ZR. Effect of size and charge on 
pharmacokinetics and in vivo MRI contrast enhancement of biodegradable 
polydisulfide Gd(III) complexes. J Control Release. 2006;112(3):350-356. 
 
35. Lu ZR, Wu X. Polydisulfide Based Biodegradable Macromolecular Magnetic 
Resonance Imaging Contrast Agents. Isr J Chem. 2010;50(2):220-232. 
 
36. Ersoy H, Rybicki FJ. Biochemical safety profiles of gadolinium-based 





37. Morcos SK. Extracellular gadolinium contrast agents: differences in stability. Eur 
J Radiol. 2008;66(2):175-179. 
 
38. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics 
and the toxicity of gadolinium complexes. Magn Reson Imaging. 1990;8(4):467-
481. 
 
39. Laurent S, Elst LV, Copoix F, Muller RN. Stability of MRI paramagnetic contrast 
media: a proton relaxometric protocol for transmetallation assessment. Invest 
Radiol. 2001;36(2):115-122. 
 
40. Puttagunta NR, Gibby WA, Smith GT. Human in vivo comparative study of zinc 
and copper transmetallation after administration of magnetic resonance imaging 
contrast agents. Invest Radiol. 1996;31(12):739-742. 
 
41. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) 
(Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in 
human bone tissue by inductively coupled plasma mass spectroscopy. Invest 
Radiol. 2006;41(3):272-278. 
 
42. Wu X, Zong Y, Ye Z, Lu ZR. Stability and biodistribution of a biodegradable 
macromolecular MRI contrast agent Gd-DTPA cystamine copolymers (GDCC) in 
rats. Pharm Res. 2010;27(7):1390-1397. 
 
43. Lu ZR, Wang X, Parker DL, Goodrich KC, Buswell HR. Poly(l-glutamic acid) 
Gd(III)-DOTA conjugate with a degradable spacer for magnetic resonance 
imaging. Bioconjug Chem. 2003;14(4):715-719. 
 
44. Xu R, Wang Y, Wang X, Jeong EK, Parker DL, Lu ZR. In Vivo evaluation of a 
PAMAM-cystamine-(Gd-DO3A) conjugate as a biodegradable macromolecular 
MRI contrast agent. Exp Biol Med (Maywood). 2007;232(8):1081-1089. 
 
45. Wang X, Feng Y, Ke T, Schabel M, Lu ZR. Pharmacokinetics and tissue retention 
of (Gd-DTPA)-cystamine copolymers, a biodegradable macromolecular magnetic 
resonance imaging contrast agent. Pharm Res. 2005;22(4):596-602. 
 
46. Andersson A, Lindgren A, Hultberg B. Effect of thiol oxidation and thiol export 
from erythrocytes on determination of redox status of homocysteine and other 
thiols in plasma from healthy subjects and patients with cerebral infarction. Clin 
Chem. 1995;41(3):361-366. 
 
47. Deneke SM. Thiol-based antioxidants. Curr Top Cell Regul. 2000;36:151-180. 
 
48. Lu ZR, Parker DL, Goodrich KC, Wang X, Dalle JG, Buswell HR. Extracellular 




49. Zong Y, Wang X, Jeong EK, Parker DL, Lu ZR. Structural effect on degradability 
and in vivo contrast enhancement of polydisulfide Gd(III) complexes as 





A NEUTRAL POLYDISULFIDE CONTAINING  GD(III)  
DOTA MONOAMIDE AS A REDOX- SENSITIVE  
BIODEGRADABLE MACROMOLECULAR 
MRI CONTRAST AGENT  
 
Introduction 
Gadolinium chelates with high thermodynamic stability are predominantly used 
as clinical MRI contrast agents for the diagnosis of life-threatening diseases, including 
cancer and cardiovascular diseases (1,2). However, most of the clinical Gd(III) contrast 
agents are nonspecific small molecules with relatively low relaxivities and rapid vascular 
extravasation rates (3). In order to overcome these limitations,  macromolecular Gd(III) 
have been developed with improved relaxivities, specificity, and stability. 
Macromolecular Gd(III) MRI contrast agents are normally synthesized through the 
covalent incorporation of small molecular Gd(III) chelates into biocompatible 
macromolecules such as proteins, dendrimers, and natural and syntetic polymers (7-9). 
This allows the agents to have significantly improved physical chemical and biological 
properties, including a two- to  fourfold relaxivity increase due to the reduced molecular 
tumbling of Gd(III) chelates (10, 11). Additionally, macromolecular MRI agents have 
been shown to have an enhanced tumor accumulation by the enhanced permeability and 
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retention (EPR) effect, as well as a prolonged blood pool circulation (12, 13).While 
macromolecular agents have been successful in preclinical studies, their translation into 
clinical application has been hindered owing to safety concerns arising from the 
ineffective excretion, which can cause the release and long-term deposition of the toxic 
Gd3+ ions (14, 15).  
To facilitate the rapid excretion of Gd(III) chelates, environmentally labile 
chemical bonds have been incorporated into polymeric systems. These bonds allow for 
the breakdown of polymer backbones or the release of Gd(III) chelates from 
macromolecules (16,17). Examples of these cleavable bonds include acid labile bonds 
(18,19), redox-sensitive bonds (20–22) and enzymatically degradable bonds (23–25). 
These biodegradable macromolecular contrast agents have maintained the advantages of 
macromolecular contrast agents for blood pool and tumor imaging and shown minimal 
long-term tissue accumulation. Previously, we have designed and synthesized redox-
sensitive polydisulfide Gd-DTPA complexes as extracellular degradable macromolecular 
contrast agents (7,26–28). These complexes have a backbone consisting of disulfide 
bonds, which are environmentally labile in vivo. The disulfide bonds are graduallreduced 
by the plasma thiols to produce monomeric or	  oligomeric Gd(III) complexes, which are 
rapidly excreted via renal filtration (29). The polydisulfide contrast agents produced 
significant tumor contrast enhancement. However, it was found that these Gd-DTPA 
complexes exhibit low kinetic inertness and release toxic Gd(III) ions by transmetallation 
with endogenous metal ions, mainly Zn(II) ions (30). Agents with low kinetic stability 
are likely to cause nephrogenic systemic fibrosis (NSF) in a small portion of the patients 
with compromised renal function (31,32). Macrocyclic Gd(III) chelates have shown high 
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kinetic stability with no transmetallation with endogenous metal ions and appeared safe 
from NSF (31–33). 
A new generation of polydisulfides containing macrocyclic Gd(III) chelates have 
been designed and synthesized to further improve the kinetic stability of the Gd(III) 
chelates in redox-sensitive biodegradable macromolecular MRI contrast agents. (N6-
lysyl) lysine-(Gd-DOTA) monoamide and 3-(2-carboxyethyldisulfanyl) propanoic acid 
copolymers (GODC) demonstrated high kinetic inertness and superior image 
enhancement (21). GODC has a free carboxylic group on each monomer unit, and is 
anionic under physiological pH. This has a significant impact on its in vivo properties, 
including pharmacokinetics and biodistribution. 
In this study, we synthesized a neutral macrocyclic Gd(III) chelate containing 
polydisulfide N1-lysylethylenediamine Gd-DOTA monoamide and dithiobispropionic 
acid copolymers (GOLS). This agent is a neutral, redox-sensitive, and biodegradable 
macromolecular contrast agent that was prepared by the condensation copolymerization 
of N1-lysylethylenediamine DOTA monoamide and dithiobis(succinimidylpropionate), 
followed by complexation with Gd(OAc)3. In addition to analyzing the physiochemical 
properties, the chelation stability, pharmacokinetics, and biodistribution of different 
polydisulfide Gd(III) complexes were analyzed in vivo. These studies were performed in 
comparison to the clinical contrast agent Gd(HP-DO3A) and a previously reported 
polydisulfide Gd-DTPA complex, GDCC (27), in a mouse model. The effectiveness of 








(HBTU) and benzotriazol-1-yl-oxytripyrrolidino-phosphonium hexafluorophosphate 
(PyBOP) were purchased from Nova Biochem (Darmstadt, Germany). 1,4,7,10-
Tetraazacyclododecane-1, 4,7-tris-tert-butyl acetate-10-acetic acid [DOTA-tris(t-Bu)] 
was purchased from TCI America (Portland, OR). N,N-Diisopropylethylamine (DIPEA) 
and trifluoroacetic acid (TFA) were purchased from Alfa Aesar (Ward Hill, MA, USA). 
Lysine methyl ester dihydrochloride, di-tert-butyl dicarbonate (Boc2O), sodium 
bicarbonate, ethylenediamine, 3,3´-dithiobis[sulfosuccinimidylpropionate] (DTTSP) and 
Gd(OAc)3 were purchased from Sigma-Aldrich, Inc. (Louis, MO, USA). GODC was 
synthesized as previously described (21). All reagents were used without further 
purification unless otherwise stated.  
 
Synthesis of N1-lysylethylenediamine DOTA Monoamide  
Nε-Boc-Nα-Boc-L-lysine methyl ester (34) and Nε-Boc-Nα-Boc-L-lysine N-(2-
aminoethyl) amide (35) were synthesized based on reported methods. Nε-Boc-Nα-Boc-L-
lysine N-(2-aminoethyl) amide (2.6 g, 6.8 mmol) and DOTA-tris(t-Bu) (3.2 g, 5.7 mmol) 
was dissolved in DMF (8 mL). The coupling agent, PyBOP (3.5 g, 6.8 mmol), as well as 
HBTU (1.3 g, 6.8 mmol) and DIPEA (1.2 mL, 6.8 mmol), were added to the mixture. The 
reaction solution was stirred at room temperature overnight. After the reaction, EtOAc 
(80 mL) was added, followed by removal of the solvent via rotary evaporation. The 
residue was purified through preparative silica TLC (EtOAc:DCM = 2:3). The product 
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was obtained as colorless crystalline compound (yield = 56%). The purified product was 
de-protected by mixing with TFA (10 mL) and stirred overnight at room temperature. 
The desired compound N1-lysylethylenediamine Gd-DOTA monoamide was precipitated 
out in ether to give a colorless compound (yield = 92%). 1H NMR (300 Hz, D2O): 1.6 
(m, 3H), 1.9 (m, 3H), 2.1 (m, 3H), 3.1 (m, 5H), 3.4 (m, 18H), 4.0 (m, 7H). MALDI-TOF-
MS: m/z = 574.4 (M+). 
 
Synthesis of N1-lysylethylenediamine Gd-DOTA Monoamide  
and Dithiobispropionic Acid Copolymer (OLS) and Its Gd(III)  
Complex (GOLS) 
GOLS was synthesized using a method similar to one previously reported (28). 
Briefly, the polymerization was carried out by slowly adding 3,3’ -
dithiobis[sulfosuccinimidylpropionate] (DTTSP) (0.6 g, 1.1 mmol) portion by portion to 
the concentrated aqueous solution of N1-lysylethylenediamine DOTA monoamide (0.8 g, 
1.1 mmol in 0.7 mL de-ionized water) while stirring. The mixture was stirred at room 
temperature for 4 h after the addition of DTTSP. The product was purified via dialysis 
against de-ionized water using dialysis membrane with a molecular weight cut-off of 
6000–8000 Da, and freeze-dried to yield the white polymer ligand (OLS). The yield of 
the reaction was 16% after purification. Gd(III) complexation was then carried out by 
stirring the mixture of the polymeric ligand OLS and twofold excess of Gd(OAc)3 in de-
ionized water for 48 h at pH 6 and room temperature. The polymeric Gd(III) complex 
was purified through size exclusion chromatography using a Sephadex® G-50 column. 
Xylenol orange was added as an indicator to monitor the complexation and purification. 
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The final product GOLS was obtained after lyophilization as white solid. The purity and 
apparent molecular weight of OLS and GOLS were determined using size exclusion 
chromatography on an AKTA FPLC system with a Superose™ 12 column (GE 
Healthcare Life Sciences). The column was calibrated using water soluble poly[N-(2-
hydroxylpropyl)methacrylamide] (HPMA) standards with a series of different molecular 
weights (Mn = 14, 23, 32 and 47 kDa). The Gd(III) content of GOLS was determined 
using inductive coupled plasma–optical emission spectrometry (ICP-OES, Perkin-Elmer). 
The hydrodynamic size of GOLS in solution was determined using dynamic light 
scattering (DLS). The DLS experiment was carried out using a Brookhaven BI- 200SM 
goniometer and BI-9000AT digital correlator equipped with a He–Ne laser (λ = 633 nm) 
at room temperature. The aqueous solution of GOLS (1.33 mg/mL) was filtered through a 
0.22 µm filter, and then measured at a scattering angle of 90. A Nanosphere™ 
polystyrene size standard (diameter = 102 nm ± 3 nm) (Thermo Scientific, Waltham, 
MA, USA) was analyzed in line to confirm accuracy. 
 
Relaxivity Measurement   
The T1 relaxivity of GOLS was determined on a Bruker minispec® relaxometer 
(1.5 T, 60 Hz) at 37 °C, and a Bruker 7.0 T MR BioSpec small animal scanner. GOLS 
solutions containing a gradient of 0.2, 0.4, 0.6 and 0.8mMof Gd(III) were prepared. At 
1.5 T, the T1 values of these solutions were measured with the relaxometer using an 
inversion–recovery pulse sequence. Similarly, Bruker’s inversion recovery sequence with 
an echo planar (EPI) readout was used to determine the T1 values at 7.0 T. The 
longitudinal relaxivity (r1) was calculated from the slope of the 1/T1 versus Gd(III) 
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concentration plot. The transverse relaxivity (r2) was measured similarly; the T2 values 
were determined using a Carr–Purcell–Meiboom–Gill (CPMG) spin echo sequence at 1.5 
T. Additionally, Bruker’s standard multi-slice–multi-echo (MSME) sequence was used to 
measure the T2 values at 7.0 T (TE = variable, TR = 2000 ms, flip angle = 180°, slice 
thickness = 1 mm, slice number = 5, averages = 2, matrix = 128 × 64, field of view = 3 
cm × 3 cm, resolution = 0.0234 × 0.3 mm). The Gd(III) content of the sample was re-
confirmed using ICP-OES after the relaxivity measurement. 
 
In Vitro Degradation of GOLS   
GOLS (0. 42 mM-Gd) and cysteine (15 µM) were incubated together in PBS 
buffer (pH=7.4) at room temperature for 6 hours. The change of molecular weight of 
GOLS over time during the incubation was monitored using size exclusion 
chromatography on an AKTA® FPLC system with a Superose® 12 column.  
 
In Vitro Kinetic Stability of GOLS  
GOLS (0.42 mM-Gd) was incubated with ZnCl2 (50 µM) in PBS buffer at 
physiological pH under 37°C for 2 hrs. Samples before and at 30, 60 and 120 minutes of 
incubation were collected, then went through the PD-10 column (GE Health Science) to 
separate the polymer bound and free Gd(III) species. The Gd(III) content in polymer after 
separation was determined using ICP-OES (Perkin-Elmers). The percentage of polymer 
bound Gd(III) post-incubation versus pre-incubation was calculated. The value was 
compared with that of our previously reported linear-chelates-based polymeric agent, Gd-
DTPA cystamine copolymers (GDCC, 0.42 mM Gd). In addition, GOLS and GDCC 
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incubated with Zn2+ free PBS buffer were used as negative controls. 
  
MRI Experiment 
Female BALB/c mice weighing 18-22 g were purchased from Charles River 
(Wilmington, MA, USA). The animals were cared for under an animal protocol approved 
by the IACUC of Case Western Reserve University. 4T1 mouse breast cancer cells (5 x 
104 cells) were inoculated into the inguinal mammary fat pads of each mouse, generating 
an orthotopic mouse model of malignant breast cancer. Contrast-enhanced MR 
examinations were performed when the tumor size reached 0.5-1.0 cm in diameter, as 
measured by a caliper. Anaesthetization of the tumor bearing mice was initially 
conducted using 2.5%-3.5% of isoflurane in oxygen, and then maintained with 1.5%-
2.5% of isoflurane during the MR examination. The animals were kept warm at 34°C 
using a temperature-controlling air conditioning system. Parameters such as temperature, 
respiration and electrocardiograms (ECGs) of the mice were monitored during image 
acquisition to ensure steady physical conditions. The contrast agent was intravenously 
administered via tail vein at the standard clinical dose of 0.1 mmol-Gd kg-1. A clinical 
agent Gd(HP-DO3A) (Bracco, Milan, Italy) was delivered at the same dose, as a control. 
MR diagnosis was performed before and at 1, 5, 10, 15 and 20 minutes post injection 
using a Bruker 7.0 T MR Biospec small animal scanner. A 3D FLASH pulse sequence 
(TE=2.6, TR=8.5, flip angle=25°, slice thickness=1 mm, slice number=32, average=3, 
matrix=100×512, field of view=10 cm × 3 cm, resolution=0.195 mm × 0.3 mm) and a 2D 
spin echo sequence (TE=8.06 ms, TR=500 ms, flip angle=90°, slice thickness=1.2 mm, 
slice number=16, average=2, matrix=128×128, FOV=3cm × 3 cm, resolution=0.234 mm 
 	  
140 
× 0.234 mm) were used to acquire the MR images. Three animals were used for each 
contrast agent.  
 
MR Data Analysis 
MR image analysis was performed using Bruker BioSpec Topspin software. 
Regions of interest (ROIs) were set in the heart (signal from blood), tumor and thigh 
muscle. Contrast to noise ratios (CNR) were calculated at each time point and averaged 
from different mice (n =3) for the organ/tissue. The CNR in the tumor was calculated 
using the following equation: CNR= (St - Sm)/(σn), where St and Sm denote the signal in 
tumor and thigh muscle and σn is the standard deviation of noise estimated from the 
background air. The CNR in the blood was calculated using the same equation, where St 
and Sm denote the signal in blood and thigh muscle. The p values were calculated using 
Student’s two-tailed t-test, assuming statistical significance at p < 0.05. 
 
Biodistribution Study  
The biodistribution of GOLS was determined at 2-day and 10-day post injection 
in comparison with GODC, GDCC and Gd(HP-DO3A).  At each time point, a group of 
BALB/c (male and female) were used for each agent. The contrast agent was 
administered at a dose of 0.1 mmol Gd/kg-1 via tail vain injection. The animals were 
sacrificed with an overdose of isoflurane, and the tissue samples (heart, spleen, lung, 
muscle, femur, skin, brain, liver and kidney) were collected and weighed. All the samples 
were dried in the 50°C oven for 3 days before dissolving in 1.0 ml of concentrated nitric 
acid (70%). The samples were then ten-fold diluted with de-ionized water, followed by 
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centrifugation at 4000 rpm for 25 min. The supernatant was collected for the 
determination of Gd content using ICP-OES.  
 
In Vivo Chelation Stability 
The in vivo chelation stability of GOLS was determined in BALB/c mice in 
comparison with GODC, GDCC and Gd(HP-DO3A). A total of 16 mice (male and 
female) were randomly divided into four groups (n=4 each) for the four contrast agents. 
The mice were anesthetized with 1.5-2.5% of isoflurane in oxygen, and administered 
with the contrast agents at a dose of 0.1 mmol-Gd kg-1 via tail vein injection. The mice 
were immediately placed into metabolic cages after the injection. Urine samples were 
collected during the period of 8 hrs preinjection and 0-8, 8-16, 16-24, and 24-48 hrs post 
injection from the metabolic cages. The urine samples were appropriately diluted using 
de-ionized water, then filtered to collect the filtrate. The contents of Gd(III), Zn(II), Cu 
(II) and Ca(II) in the filtrate of the urine samples were determined by ICP-OES.  
 
Results 
Synthesis of N1-lysylethylenediamine Gd-DOTA Monoamide  
and Dithiobispropionic Acid Copolymers (GOLS)  
The DOTA containing monomer, N1-lysylethylenediamine DOTA monoamide, 
was first synthesized through the carboxyl-amine coupling reactions (Figure 4.1). The 
neutral biodegradable macromolecular MRI contrast agent, N1-lysylethylenediamine Gd-
DOTA monoamide and dithiobispropionic acid copolymers (GOLS), was synthesized 
through condensation polymerization of the DOTA monoamide and 3,3´-
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dithiobis[sulfosuccinimidylpropionate] (DTTSP) (Figure 4.2). The structure of the 
monomer N1-lysylethylenediamine Gd-DOTA monoamide was verified using 1H-NMR 
and MALDI-TOF mass spectrometry. The number average and weight average molecular 
weight of the polymeric ligand OLS was 18.4 and 29.3 kDa, respectively. After 
complexation, the final product of GOLS were purified and fractionated through size 
exclusion chromatography using a Sephadex® G-50 column. GOLS with  number 
average and weight average molecular weight of GODC of 23.0 and 24.6 kDa were 
collected for in vivo animal studies. The hydrodynamic diameter of the GOLDS was 
around 3 nm as determined by DLS. The Gd(III) content in the agent was 16.1% (w/w) as 
determined by ICP-OES, corresponding to a complexation efficiency of 94.7% as 
compared with the calculated Gd content (17.0%, w/w). The longitudinal (r1) and 
transverse relaxivity (r2) of GOLS were 7.20 mM-1s-1  and 9.70 mM-1s-1 respectively at 
1.5 T, 37oC, approximately twice that of Gd(HP-DO3A) (ProHance®, 4.1 mM-1s-1 at 
1.5T, 37°C). Similarly, the longitudinal and traverse relaxivities of GOLS at 7.0 T were r1 
= 6.62 mM-1s-1 and r2 = 8.92 mM-1s-1. 
 
 Degradability of GOLS  
The polydisulfide structure of GOLS was designed so that the polymers could be 
readily degraded and excreted via renal filtration in vivo through the disulfide-thiol 
exchange reaction. The degradability of GOLS was firstly demonstrated via an in vitro  
incubation study with L-cysteine, the most abundant free thiols in plasma. As thown in 






Figure 4.1. Synthetic scheme of N1-lysylethylenediamine Gd-DOTA monoamide. 	  
Figure 4.2. Synthetic scheme of N1-lysylethylenediamine Gd-DOTA monoamide 




before incubation to 23.0 kDa, 22.5 kDa, 21.2 kDa and 19.0 at 30, 60, 120 and 240 min 
during the incubation.  Consequently, an increase of small molecular fractions (peaks 
from 30-40 min) were observed over time, indicating the process of degradation via 
incubation with free thiols. 
 
In Vitro Chelation Stability of GOLS 
The kinetic stability of GOLS against endogenous transmetallation was evaluated 
in vitro through incubation studies with ZnCl2 at plasma concentrations at physiological 
conditions mimicking the in vivo environment. Zn(II) was the major metal species 
involved in the transmetallation of Gd(III)-based contrast agents in vivo. As shown in 
Figure 4.4, a gradual loss of Gd(III) in polymer was observed with GDCC from the initial  
Figure 4.3. The apparent molecular weight (MW) distribution of GOLS (0.42 mM Gd) 
before (0 min) and after incubation with L-cysteine (15 µM) in PBS buffer for 30, 60, 
120, and 240 min at 37 °C. The apparent molecular weight distribution was measured by 
size exclusion chromatograms. Before incubation (0 min), only the polymer peak of 23.0 
kDa (peak at 23 min) was observed. With incubation time of 30, 60, 120, and 240 min, 
the MW of the polymer decreased to 23.0 kDa (peak at 22 min), 22.5 kDa (peak at 23 
min), 21.2 kDa (peak at 24 min), and 19.0 kDa (peak at 25 min), with an increase of their 




100 % to 92% at 30 min, 88 % at 90 min and 82 % at 120 min during the in vitro 
Zn2+incubation. In contrast, negligible loss of Gd was observed with GOLS, similar to 
what was oberved with the control samples of GDCC and GOLS incubated with Zn(II) 
free PBS buffer. The results demonstrated the polydisulfide containing macrocyclic 
Gd(III) chelate (GOLS) possessed high kinetic inertness against transmetallation. 
 
In Vivo MR Imaging  
Figure 4.5 shows the T1-weighted 3D maximum intensity projection MR images 
of mice bearing orthotopic 4T1 mouse malignant tumor before and after intravenous 
injection of GOLS and Gd(HP-DO3A). The blood pool enhancement generated by GOLS 
was gradually decreased, but still visible at 10 min post injection. In comparison, the  
Figure 4.4. The Gd(III) content in GDCC (square) and GOLS (circle) before and in 
the incubation in PBS buffer with ZnCl2 (50 µM, filled) and without ZnCl2 (open) for 





Figure 4.5.	  3D maximum intensity projection images (coronal view) of mice bearing 
4T1 breast cancer before and at 1, 5, 10, 20, and 30 min after injection of Gd(HP-
DO3A) (A) and GOLS (B) at a dose of 0.1 mmol Gd kg-1. The major organs are 
marked as h (heart), l (liver), k (kidney), b (bladder), and t (tumor). 
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Gd(HP-DO3A) generated blood pool signals that decreased sharply in 1 min post 
injection, and become negligible at 5 min post injection. Signal intensity in the kidneys 
decreased over time, while that in the urinary bladder increased for both agents, 
indicating the elimination of both agents through kidney filtration. The bladder 
enhancement was first observed at 1 min post injection for Gd(HP-DO3A), and 5 min for 
GOLS, indicating slightly slower excretion of the macromolecular agent. Figure 4.6 
shows the axial T1-weighted 2D spin-echo tumor images before and at various time 
points after injection of GOLS and Gd(HP-DO3A). GOLS generated more significant 
and prolonged signal enhancement in the tumor than Gd(HP-DO3A). As shown in Figure 
4.7, GOLS generated significantly higher CNR in blood than Gd(HP-DO3A) in the first 
10 min post injection. GOLS also produced a more than twofold CNR increase in the 
tumor compared with Gd(HP-DO3A) for at least 30 min. 
 
Biodistribution 
Figure 4.8 shows the biodistribution of Gd(III) in the major organs and tissues, 
including the heart, spleen, lung, muscle, femur, skin, brain, liver, and kidney of mice, at 
2 days and 10 days after intravenous injection of GOLS, GODC, GDCC, and Gd(HP-
DO3A) at 0.1mmol Gd kg-1. The polydisulfide agents GOLS, GODC, and GDCC had 
similar low Gd(III) distribution in the heart, spleen, lung, muscle, femur, skin, and brain 
at both time points to Gd(HP-DO3A). The agents showed higher Gd(III) concentration in 
the liver and kidney than in the other organs. The neutral polydisulfide agent GOLS 
showed much lower accumulation in the liver and kidneys than the negatively charged 



































































































































Figure 4.7. Contrast-to-Noise Ratio (CNR) of blood pool (A), and tumor (B) of mice 
bearing malignant breast cancer before and at different time points after 
administration of Gd(HP-DO3A) (open) and GOLS (filled) (*p < 0.05). Data 
presented as mean ± SD. 
A 
*	   *	   *	   *	   *	  
*	   *	  
*	  







Figure 4.8.	   Biodistribution of Gd(III) in Balb/c mice 2 days (A) and 10 days (B) after 
intravenous injection of GOLS, GODC, GDCC, and Gd(HP-DO3A) at a dose of 0.1 mmol-




post injection, which further decreased at 10 days post injection. Approximately 0.3% 
and 0.1% of injected GOLS was measured in the liver and kidneys 10 days post injection, 
lower than that of GDCC (0.5% of injected dose/liver, 0.3% of injected dose/kidney) and 
GODC (0.9% of injected dose/liver, 0.3% of injected dose/ kidney) (p < 0.05). Overall, 
the neutral agent GOLS had much lower long-term body retention than GODC and 
GDCC. 
 
In Vivo Chelation Stability 
Figure 4.9 shows the concentrations of Gd(III), Zn(II), Ca(II), and Cu(II) in the 
urin samples collected before and at different time periods of 0–8, 8–16, 16–24, and 24–
48 h after intravenous administration of GOLS, GODC, GDCC, and Gd(HP-DO3A). 
Most of the contrast agents were excreted through renal filtration within the first 8 h post 
injection. The Gd(III) urine levels were comparable among GOLS, GODC, and Gd(HP-
DO3A). The linear agent GDCC had lower Gd(III) concentrations than the other agents. 
In correlation, there was an significant increase of Zn(II) concentration in the urine 
samples collected in the first 8 h post injection of GDCC (p < 0.05), indicating 
transmetallation of GDCC with endogenous Zn(II) ions. There was no change in Zn(II) 
concentration in the urine samples from the mice injected with the macrocyclic agents 
GOLS, GODC, and Gd(HP-DO3A). No significant change of the urine Cu(II) and Ca(II) 
content was observed during different time periods after injection of the contrast agents, 
indicating the chelation stability of the tested agents. The result demonstrated the high 
chelation stability of the neutral polydisulfide containing macrocyclic Gd(III) chelates 









Figure 4.9. Concentrations of Gd(III) (A), Zn(II) (B), Ca(II) (C), and Cu(II) (D) 
measured in urine before and after administration of GOLS, GODC, GDCC, and 













GOLS is a neutral alternative to the previously developed macrocyclic 
polydisulfide GODC. We have shown that negatively charged GODC is readily degraded 
in vivo and effective for blood pool and cancer MRI. However, the negative charges on 
GODC might complicate biodistribution and elimination of the agent due to non-specific	  
charge interaction with tissue. The neutral agent GOLS was designed to eliminate those 
potential nonspecific tissue interaction. The T1 and T2 relaxivities of GOLS were slightly 
smaller than those of GODC (r1 = 8.25 mM-1 s-1 and r2 = 10.08 mM-1 s-1), but much 
higher than the clinical agent Gd(HP-DO3A). Similar to GODC, the polymer chains of 
GOLS were readily reduced by L-cysteine, the most abundant free thiol in plasma 
(29,36). The in vivo study validated the degradation mechanism through analysis of the 
urine metabolites of GODC using mass spectrometry. It was shown in both in vitro and in 
vivo studies that GOLS and GODC demonstrated high kinetic inertness against 
transmetallation with endogenous metal ions, particularly Zn(II) ions. Since both agents 
contain Gd-DOTA monoamide chelates, their in vivo kinetic inertnesses are similar to the 
clinical macrocyclic agent Gd(HP-DO3A). They have a much higher kinetic inertness 
than GDCC, a polydisulfide agent based on linear chelates. High kinetic inertness of 
Gd(III)-based MRI contrast agents is a critical safety parameter for complete and intact 
excretion of the agents from the body. 
GOLS demonstrated similar blood pool and tumor contrast enhancement to 
GODC, which was superior to the clinical agent Gd(HP-DO3A). The strong and 
prolonged blood pool enhancement of GOLS was a result of increased relaxivity and 
extended blood circulation. Strong bladder enhancement was observed at 5 min post 
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administration of GOLS, which was slower than that of Gd(HP-DO3A) but faster than 
that of GODC (10 min). This indicates the macromolecular feature and strong 
degradability of GOLS. The gradual increase of bladder signals indicated that GOLS 
could be readily excreted via renal filtration. The neutral macrocyclic chelate based 
biodegradable macromolecular MR contrast agent GOLS was advantageous for contrast-
enhanced blood pool and tumor imaging over the clinical agent Gd(HP-DO3A), and was 
readily excreted via renal filtration. 
GOLS exhibited similar retention in most organs and tissues to the clinical agent 
Gd(HP-DO3A), but slightly higher retention in the liver and kidneys. However, the 
retention of GOLS in the liver and kidneys was much lower than that of GODC and 
GDCC. The negatively charged GODC had significantly higher liver retention than 
GOLS, which could be attributed to the relatively slower in vivo excretion of GODC and 
non-specific interaction of the liver with negative charges of the agent. Nevertheless, the 
polydisulfide MRI contrast agents, including GDCC, had much lower long-term tissue 
retention than other non-degradable macromolecular MRI contrast agents, as shown in 
our previously publications (37,38). In addition, the liver and kidney retentions of the 
three polydisulfide agents were dramatically lower than those of some other reported 
macromolecular Gd(III) agents such as the second-generation Gd-DTPA 
polypropyleneimine dendrimer conjugate (7 kDa) (45% of injected dose in rats 14 days 
after injection) (39) and carboxymethyl hydroxyethyl starch-(Gd-DO3A) (47% of 
injected dose remained in the body 7 days post injection) (40). The result validated our 
design hypothesis that the neutral GOLS would minimize non-specific tissue interaction 
and result in more complete elimination than negatively charged GODC. The comparable 
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long-term tissue retention of GOLS to the clinical agent Gd(HP-DO3A) is an 




A neutral polydisulfide polydisulfide containing Gd(III) DOTA monoamide, 
GOLS, was synthesized and evaluated as a new generation of biodegradable 
macromolecular MRI contrast agent with high chelation stability. GOLS was readily 
reduced by endogenous thiols into smaller oligomers that were excreted from renal 
filtration. It possessed high kinetic inertness against transmetallation with endogenous 
metal ions both in vitro and in vivo. GOLS produced superior blood pool and tumor 
contrast enhancement to small molecular clinical contrast agents. Most importantly, 
GOLS resulted in minimal long-term tissue retention, comparable to a macrocyclic 
clinical contrast agent Gd (HP-DO3A). The neutral biodegradable macromolecular 
contrast agent GOLS has the potential to be developed as a safe and effective 
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SUMMARY AND FUTURE DIRECTIONS 
 
Summary 
The purpose of this research was to promote the clinical translation of 
macromolecular contrast agents for noninvasive MR blood pool imaging by developing 
biodegradable polymeric contrast agents of good safety and high efficacy. The work was 
an extension of our previous research on polydisulfide system, which demonstrated 
favorable cancer diagnosis efficacy and efficient in vivo degradation (1-4). However, the 
previous system was developed based on the kinetically labile linear Gd(III) chelates, 
whose safety concerns can potentially hinder their further clinical interpretation. To 
address this issue, we have developed two alternative polydisulfide systems based on two 
different chelate species: the manganese chelates and the more kinetically inert 
macrocyclic Gd(III) complexes. 
 
Manganese-based Polydisulfides 
Recently, the Gd(III)-based contrast agents have been found in association with 
nephrogenic systemic fibrosis (NSF), a severe disease affecting a small percentage of the 
patients with kidney deficiency who had a history of the exposure to Gd(III)-based 
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contrast agents, especially the linear nonionic chelates (5-10). Although the cause for 
NSF is still unclear, the design and development of effective non-gadolinium contrast 
agents with lower toxicity may alleviate the safety concerns over MRI contrast agents. 
Paramagnetic manganese(II) chelates or compounds are an alternative class of MRI 
contrast agents. As an endogenous metal, the manganese-based contrast agents exhibit 
unique biodistribution pattern and effective contrast enhancement in the myocardium, 
liver, and brain (11, 12). The main limitation of the manganese-based contrast agents is 
their relatively low relaxivities, which requires a large dose to generate sufficient contrast 
enhancement for diseased area.  However, a high dose of manganese-based contrast 
agents may lead to unexpected toxic side effects.  Chemical modifications of manganese 
based contrast agents may result in more effective non-gadolinium contrast agents by 
improving their relaxivities and optimizing their pharmacokinetics and biodistribution 
(13-17).   
In this study, we aim to develop Mn(II)-based biodegradable macromolecular 
contrast agent as an alternative for Gd(III)-based contrast agents (18). Two types of 
polydisulfide Mn(II) complexes, Mn-DTPA cystamine copolymer, and Mn-EDTA 
cystamine copolymer, were synthesized and evaluated. The polymeric ligands were 
synthesized based on reported protocols, followed by Mn(II) complexation. The T1 
relaxivity of the polydisulfide Mn(II) complexes was increased as compared to that of 
MnCl2 due to the increase of molecular size, which significantly prolonged their 
rotational tumbling time, resulting in relaxivity increase. Moreover, the relaxivities of 
these Mn(II)-based polydisulfides were comparable to that of the previously developed 
polydisulfide Gd-DTPA, possibly due to the faster water exchange rate of manganese 
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complexes than that of the gadolinium chelates which compensate the lower intrinsic 
paramagnetism of manganese (19). Comparing the relaxivity of the two Mn(II) 
polydisulfides, Mn-EDTA cystamine copolymers (6.41 mM-1s-1) had higher r1 relaxivity 
than Mn-DTPA cystamine copolymers (4.74 mM-1s-1) because of the extra inner sphere 
water binding site the EDTA agent provides.  
The degradation and kinetic stability of the two polydisulfide Mn(II) complexes 
were evaluated through in vitro incubation study. The two agents were gradually 
degraded in the presence of endogenous free thiol at plasma concentration. The kinetic 
stability study revealed potential transmetallation of Mn(II)-based contrast agents with 
calcium. In vitro incubation of the polydisulfides with calcium revealed lower extent of 
transmetallation associated with Mn(II)-EDTA cystamine copolymers than Mn(II)-DTPA 
cystamine copolymers. 
The efficacy of the two agents in MR cancer diagnosis was studied on nu/nu 
athymic mice bearing MDA-MB-231 breast cancer xenografts. The Mn(II)-based 
polydisulfides generated less blood pool and tumor enhancement in comprison to Gd(III)-
based contrast agents. Polydisulfide Mn(II) complexes also resulted in strong and 
prolonged contrast enhancement in the liver, while Gd-DTPA cystamine copolymers had 
much less contrast enhancement in the liver. Similar to other reported Mn(II) chelates, 
polydisulfide Mn(II) complexes resulted in prominent contrast enhancement in the liver 
and myocardium.  Macromolecular Mn(II) complexes have a potential to be developed as 






To address the potential safety issue with our previously developed polydisulfide 
Gd-DTPA, we have developed and evaluated two polydisulfide Gd-DOTA as a new 
generation of Gd(III)-based polydisulfides (20, 21). The agents were designed to 
maintain the polydisulfide backbone, but incorporate the macrocyclic chelates instead of 
the linear chelates to ensure high kinetic inertness of the system. The first macrocyclic 
polydisulfide we have developed was a copolymer of a lysine-based Gd-DOTA 
monoamide and 3-(2-carboxyethyldisulfanyl)propanoic acid (GODC), synthesized 
through condensation polymerization. As the previously reported polydisulfides, GODC 
was demonstrated to be readily degraded through the thiol-disulfide exchange 
mechanism. Our in vitro transmetallation study demonstrated significantly higher kinetic 
inertness of this new system over a previously developed polydisulfide Gd-DTPA, 
GDCC, indicating higher safety potential of the agent in clinical application. GODC 
showed significant advantage in tumor diagnosis than the clinical agents. However, the 
extra free carboxylic group on the monomer unit of GODC rendered the polymer charge 
negatively under physiological pH, and resulted in potentially unfavorable biological 
features. As demonstrated in our previous studies, the negatively charged polydisulfides 
showed slower degradation than the neutral polydisulfides. Since the plasma thiols are 
also negatively charged, the degradation through thiol-disulfide exchange reaction can be 
hindered via charge repulsions, resulting in comparably slower degradation, and 
consequently longer tissue retention of the agents. In addition, the charge repulsion effect 
can lead to increase of the hydrodynamic volume of GODC, which might further affect 
its elimination through renal filtration.  
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To extend the family of the macrocyclic polydisulfides, we have further 
developed a neutral alternative of GODC. Rather than using the negatively charged lysine 
linkages between the macrocyclic chelates and the polymeric backbone, neutral linkers of 
ethylenediamine were incorporated in the new polydisulfide Gd-DOTA conjugate, N1-
lysylethylenediamine Gd-DOTA monoamide and dithiobispropionic acid copolymers 
(GOLS). GOLS was prepared in a similar route as GODC through copolymerization of 
the Gd-DOTA conjugated monomer and a disulfide-contained monomer. The 
physiological properties of GOLS, such as molecular weight, hydrodynamic diameter, 
Gd(III) content, and relaxivity, were determined. Although GODC and GOLS showed 
similar molecular weight, the actual hydrodynamic volume was different as shown in the 
DLS results. The negatively charged GODC had a slightly larger size than GOLS due to 
charge repulsion on the polymeric backbones, which caused differences in relaxivity and 
degradability between the two macrocyclic polydisulfides. In comparison, GOLS had 
slightly lower relaxivity, but faster degradability than GOLS. In vitro kinetic stability 
evaluation showed high kinetic inertness of GOLS, similar to that of GODC. The efficacy 
of GOLS in MR tumor diagnosis was assessed on an orthotopic mouse breast cancer 
model. The agent generated advantage in tumor and blood pool imaging than clinical 
agents. The blood pool enhancment of GOLS appeared to decrease faster than GODC, 
possibly due to its faster degradation. The pharmacokinetics of GODC and GOLS were 
compared on mice. The distribution half life of GODC was slightly but not significantly 
longer than that of GOLS. No difference of elimination half life was observed between 
the two agents. The extent of tissue retention of the two agents was evaluated through 
short-term and long-term biodistribution study, in comparison to the polydisulfide Gd-
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DTPA agent GDCC and the clinical agent ProHance®. The polymeric agents showed 
significantly higher liver and kidney retention after 10 days of administration. The order 
of tissue deposition was GODC > GDCC ≥ GOLS. The prolonged deposition of GODC 
might be a result of its negative charge. In vivo transmetallation was compared among 
GOLS, GODC, GDCC, and ProHance® via analysis of the metal metabolite content in 
mouse urines. The biodistribution study showed minimal tissue deposition of GOLS. The 
efficacy and safety evaluation suggested GOLS as a safe and effective polymeric 
candidate for clinical MR cardiovascular imaging and cancer prognosis. 
 
Future Direction 
Both the Mn(II) polydisulfides and the Gd-DOTA polydisulfides showed their 
strength on different areas of disease diagnosis, and are potentially safe to be applied 
clinically. The Mn(II)-based contrast agents are better imaging agents for the diagnosis of 
liver dysfunction and myocardium diseases. The Gd-DOTA polydisulfide have 
advantages on MR blood pool imaging, including MR angiography and cancer diagnosis. 
These agents are conveniently prepared and characterized.  
 
Development of Polydisulfide Mn(II) Using Chelates with Higher Stability 
We have shown in this study that polydisulfide Mn(II) complexes had better 
relaxivity, pharmacokinetics, clearance, and in vivo enhancement than MnCl2. In 
comparison to some recently reported dendritic agents and colloidal systems (7-11, 26), 
our polydisufide-based Mn(II) contrast agents, designed to passively target tumor,  
showed relatively higher relaxivity and favorable pharmacokinetics.  However, the main 
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limitation of currently available Mn(II) complexes is their low complexation stability, 
including both thermodynamic and kinetic stabilities. Further studies are needed to design 
Mn(II) chelates with high thermodynamic and kinetic stability in order to develop novel 
Mn(II)-based contrast agents and to expand their application in MR imaging of other 
tissues and organs.  The magnetic property of Mn(II) based agents are also different from 
that of Gd(III)-based contrast agents.  Mn(II) complexes often have much higher T2 
relaxivity, which can significantly reduce the signal in T1-weighted imaging.  This could 
be overcome by designing better imaging sequence to reduce T2 effect in T1-weighted 
MRI in the future studies. 
 
Development of Polydisulfide Gd-DOTA with Symmetrical Structure 
 The monomer of GODC and GOLS was unsymmetrical, causing the final product 
of both agents with three possible arrangements of the Gd-DOTA monoamide in the 
polymer chains: two α-amines of separate Gd-DOTA monoamide molecules connected to 
the same DTTSP molecule, two ε-amines connected to the same DTTSP molecule, and 
one α-amine and one ε-amine connected to DTTSP. Due to this unsymmetrical structure, 
cyclization byproducts can be formed during the polymerization. Although we expect 
minor affect of unsymmetrical structures, it is desirable to develop polymers with 
symmetrical structure to ensure consistent quality and repetition of the result. The 
symmetrical polymers should be easy to achieve. Firstly, a different Gd-DOTA contained 
monomer with symmetrical structures should be synthesized, then copolymerized with 




Application of Polydisulfide Gd-DOTA in Tumor Evaluation 
Since the polydisulfide Gd-DOTA are advantageous in the diagnosis of cancer 
and blood pool imaging. These agents can have high strength on the more advanced MR 
analysis of tumor staging, which provides clues of treatment response of cancer, leading 
to effective and individualized treatment. In the experimental design, xenograft malignant 
tumor models will be developed, followed by periodical treatment. The tumor length (L), 
width (W) and height (H) will be measured daily before and after treatment using a 
caliper. The tumor volume will be calculated. The volume growth-time profile will be 
drawn, and its correlation with the predicted parameters from DEC-MRI will be 
compared. MR studies will be performed before treatment, and at different time points 
post administration of the treatment agents using the DCE-MRI sequences. The 
evaluation of DCE-MRI will be performed using physiological model mimicking the 
microenvironment of tumor. The prediction will be compared with the physical 
evaluation of tumor volume. The estimation of treatment response should be more 
accurate using the polydisulfide Gd-DOTA in compared with that of the clinical agents. 
 
Development of Multifunctional Agents by Adding Targeting  
Groups or Treatment Agents 
The application of the polydisulfide system can be extended beyond imaging 
agents by conjugating targeting peptides and cancer treatment groups. The current 
polydisulfides are designed to target tumor passively via the enhanced retention and 
permeation (EPR) effect. Adding targeting groups on the polydisulfide will further 
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